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Abbreviation 
 
Fe@C-MNPs carbon-coated magnetometallic iron nanoparticles 
® registered mark 
µCi microcurie  
⁰C  degree Celsius 
99Mo isotopes of molybdenum-99 
99mTc metastable nuclear isomer of technetium-99 
a.u. absorbance unit 
Ab  antibody 
Ag  antigen 
AP  alkaline phosphatase conjugate 
Arg arginine 
bp  base pair 
cDNA  complementary DNA 
CDR  complementarity determining region 
CEA carcinoembryonic antigen 
CH  constant heavy chain domain 
CL constant light chain domain 
CNT carbon nanotube 
Cys cystine 
DNA  deoxyribonucleic acid 
DTT dithiothreitol 
ECD 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
eGFP enhanced green fluorescent protein 
ELISA  enzyme linked immunosorbent assay 
Fab  antigen binding fragment  
Fc  fragment crystallizable region 
FR  framework regions 
GBq giga becquerel 
Gln glutamine 
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Glu glutamic acid 
Gly glycine 
GPI  glycosyl-phosphatidyl-inositol 
HCAb  heavy-chain only antibody 
HER2 human epidermal receptor 2 
HPRI human placental RNase inhibitor 
hPSA human prostate specific antigen 
HRP  horse radish peroxidase 
IFA  indirect immunofluorescence assay 
Ig  immunoglobulin 
IgG  immunoglobulin G 
IgG-Nb  Nb of the IgG-isotype (with known antigen specificity) 
IMAC  immobilized metal affinity chromatography 
IPTG  isopropyl-β-D-thiogalacto-pyranoside 
ITLC instant thin layer chromatography 
ka  association constant 
kb  kilo base 
kBq kilo becquerel 
KD  equilibrium dissociation constant 
kd  dissociation constant 
kDa  kilo dalton 
Leu leucine 
mAb  monoclonal antibody 
MBP  mannose binding protein 
MITI microwave induced thermoacoustic imaging  
MNP magnetic nanoparticles 
mRNA  messenger ribonucleic acid 
MUC mucin 
MW  molecular weight 
MWCO molecular weight cutoff  
MWNT multi-wall carbon nanotube 
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Nb  Nanobody® 
NHS N-hydroxysuccinimide  
NP  nanoparticles 
OD  optical density 
PBL peripheral blood lymphocyte 
PBMC peripheral blood mononuclear cell 
PE  periplasmic extract 
Phe phenylalanine 
pI iso-electric point 
RDT  rapid detection test 
RT-PCR  reverse transcriptase-polymerase chain reaction 
SEC  size exclusion chromatography 
SmCB Schistosoma mansoni cathepsin-B 
SmSE secretory execratory Schistosoma mansoni 
SPR  surface plasmon resonance 
SWNT single-wall carbon nanotube 
Taq  Thermus aquaticus 
TAT thermoacoustic tomography 
TCT thermoacoustic computed tomography 
Trp tryptophane 
Tyr tyrocine 
™ trademark 
Val valine 
VH  variable domain of the heavy chain of a conventional antibody 
VHH  variable domain of the heavy chain of a heavy-chain only antibody 
VHH2 bi-valent VHH 
VL  variable domain of the light chain of a conventional antibody 
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Abstract 
 
Nanotechnology has enthused excessive expectations in recent years, particularly in the biology 
and biomedical fields. Carbon-coated metallic nanomagnets reveal significant physicochemical 
properties, which are referred to as superparamagnetism, that when designed appropriately can 
be utilized to generate novel diagnostic and therapeutic applications for a wide range of 
biologically hazardous species. Schistosomiasis is a chronic parasitic disease that can infect both 
humans and animals, particularly cattle. It is caused by a trematode blood fluke of the genus 
Schistosoma which belong to the schistosomatidae family. At least 200 million individuals are 
infected in 75 countries while 600 million people are exposed to infection and are potentially 
victim of this parasite. Schistosomiasis is still recognized as one of the most neglected disease, 
the current available diagnostic techniques are deficient in accuracy and are incapable of 
identifying the disease in its early stages. Moreover, they suffer from prolonged examination 
time. Besides, the poorly available therapeutic drugs started to lose their efficacy and the parasite 
started to develop resistance against most of them, which create an imperative need for 
developing novel diagnostic and therapeutic tools. The humoral immune response of the 
Camelidae is unique since these animals possess functional heavy-chain only antibodies in 
addition to the classical antibodies. Thanks to recombinant DNA technology, a series of single-
domain antigen binding entities can be produced against specific schistosome’s parasite antigens. 
These binders possess a number of distinctive biophysical properties that offer particular 
advantages in various theranostic applications. Finally, nanomagnetism was selected to represent 
a certain phenomena through which we demonstrated, to our knowledge for the first time, the 
successful construction of effective and functional bioconjugate system which is appropriate for 
a plethora of diagnostic and therapeutic applications. The main thrust of this research work was 
towards the developing of single domain antibodies against Schistosoma mansoni gut specific 
antigen and execratory secretory antigen. In parallel, state-of-the-art methodologies were 
implemented for constructing a bioconjugate system composed of sdAb and graphene-coated 
metallic nanomagnet tagged with a carboxyl terminal. Finally, the well-established metastable 
technetium-99 (99mTc) is used for labeling the conjugate for studying the possibility of active and 
magnetic targeting of the nano-structured system – i.e. 99mTc-sdAb-Fe@C-MNP conjugates.  
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Aim of this research 
 
In this study, we aimed at studying the possibility of generating single domain antibodies 
(hereinafter referred to as sdAb, VHH, Nb or Nanobodies®) against species-specific antigens of 
Schistosoma mansoni for diagnostic and therapeutic applications. Our interest has been focused 
on two antigens (i) S. mansoni Cathepsin B, and (ii) S. mansoni Execratory Secretory antigen. 
Furthermore, proving the concept of constructing novel conjugate systems through a distinctive 
bio-conjugation approach: 
 Constructing of sdAb-Metallic Graphene-Coated Magnetic Nanoparticles for a variety of 
in vitro and in vivo diagnostic and therapeutic applications (i.e. TAT and MRI imaging, 
active/magnetic targeting and magnetic hyperthermia). 
 
Specific objectives of the study 
First Chapter: 
 Camel immunization with Schistosoma mansoni native antigens of Cathepsin B (SmCB) 
and secretory execratory (SmES). 
 Construction of Nanobody® immune cDNA and phage display libraries. 
 Generation of SmCB binding Nanobodies® 
 Generation of SmES binding Nanobodies® 
 Characterization of Nb-Ag binding interaction via ELISA assays 
 
Second Chapter: 
 Generation of Nb-Graphene-Coated MNP 
 Radio-labeling of Nb-Graphene-Coated MNP system and studying of magnetic targeting 
 
Concluding Remarks and Future Challenges 
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CHAPTER 1: GENERATION OF CAMELIDAE’S SINGLE-DOMAIN 
ANTIBODIES AGAINST Schistosoma mansoni  
1 Schistosomiasis: The Disease and the Cure 
1.1  Background 
Schistosomiasis is a parasitic disease commonly known as bilharzia, the infection caused by one 
of the five different species of the parasite (trematode helminthes) of the genus Schistosoma. The 
species of prevalent seriosity are S. haematobium (dominant in Africa), S. japonicum (dominant 
in Japan, Southeast Asia and Western Pacific) and S. mansoni (dominant in Africa, Southwest 
Asia, Brazil and Caribbean). Schistosoma intercalatum and S. mekongi are recognized as the two 
less significant species that parasitize humans. The route of infection takes place during direct 
skin contact with the free-swimming stage (i.e. cercariae) while swimming or bathing in slow-
moving fresh water streams which are inhabited by intermediate host (Adel, 2001). 
The world health organization WHO estimates that there are about 200 million people 
worldwide infected with Schistosomiasis, 120 million symptomatic patients and 600 million 
individuals live at risk (WHO, 1993). In sub-Saharan Africa the estimated fatality related to S. 
mansoni and S. haematobium is about 280,000 people per year (Pearce & MacDonald, 2002). 
The range of endemicity of the disease may change either throughout movements of infected 
persons to endemic areas, or through the creation of artificial new habitat for infected snails (i.e. 
dams, canals and fields irrigated by flooding, for instance, rice fields). 
Schistosomiasis is endemic to over 70 countries, and about 85% of the 200 million 
people infected with schistosoma live in Africa (WHO, 2010). Figure 1.1 represents the recent 
distribution of the diseases worldwide and primarily highlighting the following regions: 
 Africa: Southern, Sub-Saharan, Lake Malawi. 
 Asia: Philippines, Laos, Cambodia, Japan, Central Indonesia, Mekong Delta, 
Southern China.  
 Caribbean: Antigua, Dominican Republic, Guadeloupe, Martinique, Montserrat, Saint 
Lucia. 
 Egypt: Nile River Valley. 
 Middle East: Iran, Iraq, Saudi Arabia, Syrian Arab Republic, Yemen. 
 South America: Brazil, Suriname, Venezuela. 
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Figure 1.1. Geographic Distribution of Schistosomiasis. (CDC, 2011) 
 
There are four trematode species in the genus Schistosoma, Schistosoma mansoni, S. 
haematobium, S. japonicum, and S. mekongi, cause a series of related diseases in humans 
referred to as schistosomiasis. Additionally, S. intercalatum is a parasite of cattle in West Africa 
which occasionally causes the disease in humans. Schistosomiasis is also known as: Katayama 
fever, Bilharzia or Schistosome blood-dwelling fluke worms. 
The effect of Schistosomiasis on human health was early characterized at least 4,000 
years ago in early Egyptian papyri, recent analysis could reveal immunological clues as to its 
existence in ancient mummies (Adel, 2001). In 1851, Theodor Bilharz discovered the etiology of 
Schistosomiasis in humans while he was working out of Cairo, Egypt. The German physician 
successfully identified adult male and female Schistosoma haematobium during autopsy 
examinations. Furthermore, for more than half a century the clinical symptoms of Schistosoma 
japonicum was described as a syndrome until the species was discovered in 1904. 
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In 1907, Sir Patrick Manson was the first scientist who discovered Schistosoma mansoni 
and could identify the differences in egg morphology – i.e. terminal versus lateral spine, and 
excretion pathways – i.e. fecal versus urinary, of the two separate species S. mansoni and S. 
haematobium. The life cycle details of S. japonicum were clearly elucidated in 1913 by 
Keinosuka Miyairi and Masatsuga Suzuki, they could describe the route of infection into human 
hosts and the exact dynamics of the parasite life cycles (Bigwan et al., 2012). 
The life cycles of all schistosoma species are quite comparable, all the adult worms live 
in mesenteric venules nearby liver, with the exception of S. haematobium in which adults 
migrate to urinary bladder and live in venous plexus, where it discharges eggs into fresh water 
sources through urine. All the species share the same mode of infection, infection starts in fresh 
water where snails are shedding cercaria – i.e. infective form, which penetrates the patient skin – 
e.g. human and cattle, after that cercaria develop into schistosomula which migrates to the lung. 
Afterward, schistosomula continue to migrate to the liver through the blood stream. Finally, the 
eggs enter the small intestine and excreted in the feces and deposited in fresh water where they 
hatch and release miracidium that penetrate snails. 
The schistosomes feed on their host blood (blood fluke) and are attached to the 
mesenteric venous plexus. The females secrete eggs with ciliated miracidium larva in the urine 
or stool. The miracidia are released from eggs, and they start to search for their related 
freshwater snails that serve as the intermediate host. Subsequently, the infected snails produce 
thousands of cercariae which remain in the water for months. Rivers, lakes, ponds, man-made 
reservoirs and flooding irrigation systems become typical sources of infection and have resulted 
in regional increases in schistosomiasis. On finding a host, the cercariae penetrate the host skin 
and migrate into the liver where they transform into young worms over several weeks before 
migrating to the mesenteric destination (WHO, 2010). Figure 1.2 illustrates the general life 
cycles of the three widespread schistosoma species – i.e. Schistosoma mansoni, S. haematobium, 
S. japonicum. 
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Figure 1.2. Life Cycle of Schistosoma mansoni, S. haematobium, S. japonicum. (CDC, 2010) 
 
There are three genera of freshwater snails which host miracidia of the key human 
schistosomes, Oncomelania (S. japonicum), Bulinus (S. haematobium) and Biomphalaria (S. 
mansoni). Schistosoma japonicum has competent reservoirs in many domesticated animals 
including cats, dogs, horses and cattle. Whereas, S. haematobium has no identified animal 
reservoirs, recently S. mansoni has been found to rarely parasitize monkeys and some rodents, 
but does not have any genuinely established non-human hosts (Pearce & MacDonald, 2002). 
Symptoms differ with respect to the infectious species of worm as well as the phase of 
infection. In the very beginning, itching and rash at site of percutaneous penetration of the 
cercariae is often recognized as the earliest sign of infection (usually known as Swimmer's Itch). 
Immediately afterward, fever, localized oedema and allergic reactions may occur (John & Petri, 
2006). The invasion of cercariae might initiate a wide variety of pathologies, the acute pathology 
also known as Katayama fever which is very common in tourists, travelers and other people 
accidentally exposed to transmission that include sudden fever, myalgia, fatigue and malaise. 
Figure 1.3 illustrates the foremost symptoms of cercariae penetration (i.e. Swimmer's Itch). 
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Figure 1.3. Initial Symptoms of Cercariae Penetration (Education, 2011) 
 
The acute phase is usually manifested after one to three months of infection, when the 
mature flukes start laying eggs in the mesenteric or vesical venules, patients start on complaining 
of fever and abdominal pain. The deposition of eggs in the small hepatic venules causes the 
formation of granulomas in the liver and initiation of pipestem fibrosis of the portal and 
associated veins. Later on, hepatosplenomegaly and lymphadenopathy usually occur (Pearce & 
MacDonald, 2002; Bigwan et al., 2012). 
Chronic schistosomiasis stages may be presented in a wide variety of forms, intestinal 
chronic schistosomiasis typically caused by S. japonicum and S. mansoni, where large intestines 
are habitually the site of the infection. Patients experience diarrhea with or without blood, 
dyspnoea, weight loss, diffuse abdominal pain and discomfort and hepatosplenomegaly might 
occur. However, the main lesions (situated in large bowl and rectum, bladder, kidney and liver) 
are not due to the worms but due to the trapped eggs in tissues secreting proteases that provoke 
eosinophylic inflammatory and granulomatous reactions. Figure 1.4 shows 6-year-old boy with 
gross reactive hepatosplenomegaly (left side) and 19-year-old symptomatic man (right side) with 
chronic fibrotic hepatic schistosomiasis, it illustrate sever splenomegaly, external varices, ascites, 
and growth retardation (Gryseels et al., 2006). 
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Figure 1.4. Intestinal and Hepatic Schistosomiasis (Gryseels et al., 2006) 
Urinary chronic schistosomiasis, typically caused by S. haematobium, is associated with 
painful urination (dysuria). Given that, these eggs rupture the bladder wall and cause the damage 
that can contribute to blood in urine (haematuria). In addition, they are also associated with 
greatly increased incidence of squamous cell carcinoma of the bladder. Cerebral schistosomiasis 
is most commonly caused by S. japonicum, in which the egg deposits cause local damage and 
lesions in the host central nervous system (CNS). Moreover, severe problems rooted in capillary 
blockage and subsequent ischemia (John & Petri, 2006). Figure 1.5 represents two different 
urine samples, the right sample is for normal patient, whereas, the left sample is for a patient 
with macro-haematuria due to ulceration of the bladder wall in urinary schistosomiasis (Gryseels 
et al., 2006). 
 
Figure 1.5. Haematuria Urinary Schistosomiasis (Gryseels et al., 2006) 
Hepatic chronic schistosomiasis can lead to liver fibrosis, gastrointestinal varices. The 
genital schistosomiasis, which is quite common in endemic areas, is regularly found in travelers 
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and might lead to haemospermia or ovarian lesions causing infertility. However, in 
schistosomiasis the organ function and indices remain largely unaffected for a long time when 
the infection might no longer be detectable. Many of the unspecific and multifactorial morbidity 
symptoms are clinically and epidemiologically hard to differentiate from other infections such as 
malaria or other poverty-related health problems. Finally, quite a lot of other disorders are 
usually associated with chronic schistosomiasis, the risk of colon and liver cancer increases with 
prolonged infection. It is also possible that the chronic bacterial (e.g. chronic salmonellosis) and 
trematodes infections are more than accidentally connected (John & Petri, 2006; WHO, 2010; 
Bigwan et al., 2012). 
 
1.2 Diagnosis and Therapy 
1.2.1  Diagnostic Tests 
The classical standards of diagnosing schistosomiasis are still microscopic-based examination of 
excreta – i.e. urine and stool smears. Nevertheless, concentration steps need to be included for 
mild infections or poor egg secretions. Unfortunately, the egg count poorly reflects the worm 
burden inside the host. Nevertheless, bladder or rectal biopsy specimens are also standard 
practice (Elliott, 1996). Recently, some haematological techniques correlate between the 
elevated count of eosinophil and schistosomiasis infection (Dajotoy et al., 2004).  
Additionally, sensitive antibody-based assays – i.e. methods where the schistosomes-
specific host antibodies are detected, are available. However, these approaches are restricted to 
specialized hospital settings and fail to discriminate exposure to antigens from active infections.  
Likewise, antibody tests are also available, such tests are able to screen the presence and quantify 
the somatic schistosomes’ antigens as well. Commonly, circulating anodic antigen – CAA and 
circulating cathodic antigen – CCA with monoclonal antibodies (mAbs) are successfully used. 
Despite the fact that, such screening tests do not distinguish between present and history 
infections (Fulford & Keystone, 2002).   
 
1.2.2  Management and Therapy: Current Status and Novel Approaches 
Bilharzia is treated symptomatically with various corticosteroids, a number of schistosomytoxic 
compounds currently exist such as: Praziquantel, Oxamniquine and Artemisinin. Regarding 
Praziquantel, it has insignificant toxicity to the animals and human while it exhibits an adequate 
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toxicity to the mature worm stage, it prevents worms from growing or multiplying in the body. 
Nonetheless, it is ineffective against immature stages, so that constant treatments are 
compulsory, although, recurrences of infection still highly probable. The imminent threat of an 
omnipresent resistance of helminthes to the only available drugs might happen, for this reason, 
prolonged and massive treatment with these drugs should be avoided. Indeed, Oxamniquine 
resistance has already been reported and Praziquantel tolerant schistosomes could be found in 
animals (King et al., 2000).  
In 2009, a notable study of the genome of the blood fluke Schistosoma mansoni (and S. 
japonicum as well) was published, in which the entire 363 mega-base nuclear genome of the 
blood fluke was fully analyzed, this genome encodes at least 11,809 genes (Berriman et al., 
2009). The bioinformatics approaches could successfully identify numerous metabolic 
chokepoints, in addition, via thorough chemogenomic screens a series of the parasite proteins, 
for which existing and future drugs may be effectively developed, has been pinpointed. Thus, 
such information provides a giant resource for the research community from countless aspects in 
order to develop new control tools, early diagnostic methodologies and therapeutics for the 
eradication of this serious, and yet, neglected disease. 
Without delay, it is clear that there is an urged need for developing totally new and potent 
anti-schistosomes drugs, as well as, novel and sensitive diagnostic tools either applicable in field 
tests or to mass-screening the worm burden in vivo in human and cattle. Nevertheless, identifying 
the worm location in patients is greatly required and would positively affect the entire process of 
developing robust, efficient, reliable and cost friendly theranostic endeavors. For these 
objectives, the research group set a plan up to developed highly specific, soluble, stable and 
monovalent single-domain antibodies (sdAbs) from immunized camel’s library against 
Schistosoma mansoni parasite – i.e. fully functional antibody fragment. Comprehensive 
enlightenment of the reasons behind selecting such unique antibody type is concluded from 
studying their exceptional properties which will be resourcefully described in the next section. 
Furthermore, a proof of concept experiment was developed for constructing of bioconjugate 
system of radio-labeled graphene-coated metallic magnetic nanoparticles to various sdAbs for 
diagnostic and therapeutic applications. 
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2 Camelidae’s Single-Domain Antibodies: Current Status & Numerous Possibilities 
2.1 Introduction 
The intensity of the natural immune system has gained much interest because of its importance 
in a wide range of both fundamental and applied sciences. The immunoglobulins are soluble 
glycoproteins in blood and tissue liquids that play a basic and essential role in the humoral 
immune system of vertebrates. Antibodies are synthesized by B-lymphocytes in response to 
foreign biological and chemical substances – i.e. antigens, of enormous structural variations with 
an intention to counteract, or neutralize, them. Owing to their high specificity and high binding 
affinity of antigens and to the possibility of generating antibody against practically limitless 
repertoire of antigens, antibodies and their derivatives are recognized among the most imperative 
reagents for fundamental, applied and medical research (Tillib, 2011). 
Notwithstanding the fact that camelids are economically important in the Middle East, 
North African and South American countries, their immune system was barely investigated until 
the mid-1990s. Systematically, camelid species belong to the family of Camelidae, suborder of 
Tylopoda, order of Atiodactyla (Conrath et al., 2003). Table 1.1 gives an idea about the normal 
average haematological values of camelid sera, in which it is so observable there are no 
significant disparities among different camelidae species. 
 
Table 1.1. Haematological values of camelid sera (Wernery et al., 1999) 
 Desert dromedary Bactrian camel Llama 
Platelets 240-310 x 103/µL Not available 240-310 x 103/µL 
Red blood cells 7.1-10.9 x 106/µL 10.2-13.2 x 106/µL 10.5-17.2 x 106/µL 
White blood cells 10.2-21.5 x 103/µL 10.0-15.8 x 103/µL 8.0-21.4 x 103/µL 
Neutrophils (%) 35-60 28-83 41.7-72.9 
Lymphocytes (%) 29-55 19-56 9.2-23.2 
Monocytes (%) 2-5 0-7 0-4.6 
Eosinophils (%) 2-12 0-18 0.2-21.4 
Basophile (%) 0-2 0-3 0-14 
 
Although various kits are in use to estimate the actual immunoglobulins concentration, 
they generally fail to concede consistent results (Wernery, 2001). Therefore, it is rather 
premature to propose a standard table with a reliable range of concentrations of the various 
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immunoglobulins’ isotypes, and only a qualitative description can be merely provided. 
Nevertheless, the average values from the few published data affirm that the dromedary 
immunoglobulins-G IgG includes (i) IgG1 fraction purified from sera by protein A and protein G 
chromatography of approximately 3 mg antibody per mL serum (Hamers-Casterman et al., 
1993), (ii) the IgG2 and IgG3 fractions’ concentrations are about 1 and 2 mg antibody per mL of 
serum, respectively (Nguyen et al., 2001).  
Classification of the camelid IgG is typically achieved based on the subject of 
characteristic differences in the ranges of their heavy chain molecular weight’s values. 
Epigrammatically, the conventional IgG1 is a dominant isotype of IgG antibodies comprising of 
two heavy chains (H-chains) of about 50 kDa each, and two light chains (L-chains) of 25 kDa 
each. The other two IgG fractions were named IgG2 and IgG3 which represent the camelid 
heavy chain antibodies. The absence of the constant heavy chain domain (CH1-domain) which 
was confirmed via complementary DNA (cDNA) analyses explains the H-chain molecular 
weight difference of the IgG2 and IgG3 weighed against IgG1. Characteristically, the H-chains 
of IgG2 and IgG3 are about 10 kDa lighter than those of the conventional IgG1 (De Genst et al., 
2006a). 
The average concentration of the IgG2 and IgG3 in the serum of camelids is different for 
each species. For instance, in dromedary approximately half of the concentration of the serum 
IgG repertoire corresponds to the heavy-chain antibodies. However, their concentration in llama 
serum is much lower (Muyldermans et al., 2001a; De Genst et al., 2006a). 
 
2.2 Heavy Chain only Antibodies: Discovering the Phenomena 
In 1993, a Belgian scientific group could find, by serendipity, (in the course of performing a set 
of electrophoretic analysis of immunoglobulins for the sera of assorted representatives of 
camelidae’s), that these animals incorporate in their serum a unique class of antibodies that lack 
L-chains in presence of the conventional ones, they were called heavy-chain only antibodies 
HCAbs (Hamers-Casterman et al., 1993). The antigen-binding domains of these exceptional 
camelid HCAbs consist of only one domain, termed variable domain of the heavy chain of the 
heavy-chain antibodies VHH. Such feature offers a large number of technological advantages in 
the generation of engineered antibodies, as compared with conventional antibodies which require 
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both the variable domain of the heavy chains (VH), in addition to that of the light chains (VL) to 
bind their specific antigen appropriately (De Genst et al., 2006b). 
The innate supremacy of HCAbs together with their small size, ability to recognize 
unique epitopes, sub-nanomolar binding affinity, outstanding solubility, great stability, high 
expression yields and scalable production in broad variety of expression systems have combined 
together to make them an interestingly useful class of biomolecules for various medical 
diagnostic and therapeutic applications. 
 
2.3 The Camelidae HCAbs: Originality and Unique Features  
The presence of such unique type of intrinsic antibodies as a component of the humoral immune 
system is well established, not only for camelidae’s species but also for an assortment of other 
animals. For instance, several notable studies were able to confirm the occurrence of distinctly 
unconventional antibodies in the serum of wobbegong sharks (Orectolobus maculatus), nurse 
sharks (Ginglymostoma cirratum) and in ratfish as well (Greenberg et al., 1995; Nuttall et al., 
2001). However, in these cartilaginous fishes they are commonly known as the IgNARs (Ig new 
antigen receptors). The original nature of IgNARs is visible in their gross structure organization. 
Nonetheless, HCAbs in sharks have a fairly different structure compared to camelidae’s, they are 
disulfide-bonded homodimers consisting of five constant domains and one variable domain, this 
single variable domain V-NAR is responsible for targeting antigens (Nuttall et al., 2001). Given 
that, all the work in this research study have been carried out while utilizing only camelidae 
HCAbs, from now, only details about camelidae’s will be discussed in an ample level of details.  
 
2.3.1  Originality: Introduction 
In the beginning, it was strongly suggested that these distinctive camelidae HCAbs will suffer 
huge deficiency in engendering an extensive antigen-binding complexity. Plausibly, the 
expansion of conventional forms of antibodies repertoire is formed, at first, by the random 
association of heavy and light chains. Conversely, the prominent study established by Hamers-
Casterman et al. could primarily analyze the immune response of naturally infected dromedaries, 
with Trypanosoma evansi, in which a very diverse HCAbs response against different natural 
proteins of the parasite was confirmed (Hamers-Casterman et al., 1993). Later and without a 
doubt, numerous studies could establish the possibility to generate diverse HCAbs that can target 
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a wide range of antigens (Cortez-Retamozo et al., 2004; De Genst et al., 2006b; Klooster et al., 
2007). It can be speculated that, the high frequency of mutation hotspots and the extended 
structural repertoire of antigen-binding loops along with the longer complementary determining 
regions (CDRs) contribute to the complexity of VHHs repertoire and balance, in some way, for 
the lack of the combinatorial diversity between the heavy and light chains (Nguyen et al., 2000). 
 Unlike the pathological case of heavy-chain disease in which conventional antibodies 
devoid of L-chains, these abnormalities are generated due to unusual deletion of large and 
various parts of the VH and CH1. As a result, they fail to bind antigen properly and are 
recognized as non-functional antibody fragments (Seligmann et al., 1979). In contrast, the 
camelid HCAbs evidently contribute to the immune response of the camelidae species during the 
course of infections. Thus, the VHHs derived from camelid HCAbs are fully functional and 
active in antigen recognition. In addition, their inherent features make them superior to other 
engineered variable heavy chains VH antigen-specific fragments from murine or human origins.  
In conclusion, there have been relatively few studies that could successfully isolate 
functional domains of VH from conventional antibodies (Tanaka et al., 2003) with the intention 
of minimizing their sizes, however their practical implementation was usually mired by the low 
antigen-binding affinity, poor solubility, low expression yields and unfavorably limited stability 
features (Davies & Riechmann, 1995). 
 
2.3.2  Original Amino Acids Sequence  
In camelidae’s, despite the fact that the VH and VHH are similar, to a certain extent, in their 
amino acid sequence, the most evident and reproducible remarkable distinction between the VH 
and VHH comes from the substitution of four amino acids in the framework-2 region. Such 
substitution is responsible for providing the VH with more hydrophobic characteristics – i.e. 
anchoring place for VL, than the VHH in which all the replaced amino acids residues are 
relatively more hydrophilic. Precisely, the VH’s highly conserved residues Val37, Gly44, Leu45, 
and Trp47 are substituted in VHH by Phe37 (or Tyr37), Glu44 (or Gln44), Arg45 (or Cys45) and 
Gly47 (or Leu47), as per Kabat numbering (Muyldermans, 2001b; Conrath et al., 2001a; De 
Genst et al., 2006b). 
Compared to humans, camelidae’s VHH amino acid sequence closely resembles that of 
human’s VH of family III. Nevertheless, there are still some notable differences in its 
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framework-2 and CDRs regions (Muyldermans et al., 1994; Vu et al., 1997; Harmsen et al., 
2000). As for the framework-2 region, the hydrophobic and highly conserved residues Val42, 
Gly49, Leu50 and Trp52 of the human and also of mouse VHs’ are substituted in VHHs by 
Phe42 (or Tyr42), Glu49, Arg50 (or Cys50), and frequently Gly52. However, these substitutions 
do not induce any momentous conformational rearrangements of the molecular backbone as 
revealed by many crystallographic analyses (Muyldermans et al., 2001a). 
The conversion of hydrophobic surface into a more hydrophilic one will certainly resist 
the preserved-native hydrophobic pairing with the VL (Chothia et al., 1985). Subsequently, the 
natural existence of highly conserved hydrophilic substitutions will, by all aspects, enhance the 
solubility of the isolated VHH domain compared to classical antibodies. Indeed, grafting these 
camelidae’s VHH hallmark residues onto the murine or human single domain VH (a process 
called ‘camelization’) would render the domain more soluble (Davies & Riechmann, 1994). This 
can explain the low immunogenicity of VHHs which primarily originates from their small size, 
in addition to the high homology between them and human VH of family III. Considerable 
bioinformatics’ studies confirmed the occurrence of about 80-90% homology (Desmyter et al., 
1996). Moreover, a remarkable study by Vincke and colleagues reported successful 
humanization of camelidae’s derived VHHs without compromising neither their specific function 
nor their antigen-binding kinetics (Vincke et al., 2009). 
 
2.3.3  Unique Features: Ontogeny vs. Structure and Functionality  
The structure of HCAbs’ is quite unique, the whole molecule is composed of a single variable 
domain, in which the hinge region and the two constant domains CH2 and CH3 are homologues 
to those from the classical antibodies. HCAbs are naturally devoid of light chains and also lack 
the first domain of the constant region CH1 of conventional antibodies. The variable domain of 
the HCAbs represents the anchoring site for the constant CH2 and CH3 domains. Moreover, the 
absence of the three antigen-binding loops provided by VL of VH reasonably authenticates the 
responsibility of the VHHs’ hypervariable loops for antigen recognition. Hence, there was a 
priori no reason to question the protruded elongation of the hypervariable regions, particularly 
the CDR1 and CDR3, in VHHs more than in VHs (Muyldermans et al., 2009). 
CDRs of HCAbs are very distinctive, the first amino acid of CDR1 is highly variable (Vu 
et al., 1997; Nguyen et al., 2000). In addition, the CDR3 loop of VHH contains longer loops (i.e. 
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in average 16-18 amino acids) than the same CDR of human VH (14-12 amino acids) or mouse 
VH (7 amino acids) (Muyldermans et al., 2009). The high frequent tethering by an inter-loop 
disulfide bond, typically between CDR1 and CDR3, (Muyldermans et al., 1994; Harmsen et al., 
2000) possibly responsible for assisting in the unique loop structure (Muyldermans, 2001b). In 
summary, the presence of the additional intra-domain disulfide bond (connecting CDR3 and 
CDR1 or CDR1 and CDR2) may have two outcomes: (i) anchoring the CDR3 against the former 
interface and (ii) predispose the orientation of CDR3 for appropriate presentation to the antigen 
(Bond et al., 2003). 
 
 
Figure 1.6. Schematic Presentation of the Camelid Conventional and Heavy-Chain IgGs and 
the Antigen-Binding Fragments thereof. A. From left to right, the composition of a classical 
antibody (left), a heavy-chain antibody (middle) and a single-domain antigen-binding entity 
derived from a heavy-chain antibody, the VHH (right). B. The sequence organization of the VH 
and VHH with framework and CDR’s is schematically represented at the top of this panel 
(Muyldermans et al., 2009). C. The VHH three complementarity determining regions (CDRs) of 
the antigen-binding paratope are depicted as colored loops: CDR1 red, CDR2 green, and CDR3 
blue. (Wesolowski et al., 2009) 
 
The absence of the CH1 Region in VHH while their sequence is present in the genomic 
DNA signifies that the CH1 sequences are removed during splicing due to a point mutation at the 
5’ end of the CH1-hinge intron – i.e. at the 3’ end of the CH1 exon (Nguyen et al., 1999). 
Understandably, the instantaneous secretion of camelid HCAbs may account for this absence. In 
conventional antibodies, the major function of the CH1 domain is to serve as binding site for the 
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H-chain chaperoning protein BiP, which prevents the secretion of the premature antibody from 
the endoplasmic reticulum (ER). Once the BiP is replaced by the light chain the mature 
antibodies are secreted (Hamers-Casterman et al., 1993).  
Finally, the presence of the fragment crystallizable region Fc part of the camelidae’s 
HCAbs explicates their ability to exert effector functions for target cell destruction through 
various means: (i) antibody dependent cell-mediated cytotoxicity (ADCC), (ii) antibody 
dependent cellular phagocytosis (ADCP) and (iii) complement dependent cytotoxicity (CDC) 
typically as the conventional antibodies (Atarhouch et al., 1997; Nguyen et al., 1999; Chan & 
Carter, 2010). 
  
2.3.4  Unique Features: Higher Stability, Solubility and Binding Affinity 
The remarkable high stability and the ability of refolding of VHHs make them an exceptionally 
potential agent for numerous possibilities where harsh conditions are habitually encountered. 
After prolonged heat treatment at relatively elevated temperatures (e.g. 70 ⁰C and 90 ⁰C), the 
VHHs demonstrate high thermotolerance and unique ability to retain more than 80% of their 
original binding affinity (Van der Linden et al., 1999; Ladenson et al., 2006). Moreover, VHHs 
exhibit superior degradation-resistance when they exist with various types of protease (protein) 
enzymes (Hussack et al., 2011). Additionally, VHHs reveal highly stable to extremes pH ranges, 
Dumoulin and his colleagues confirmed that VHHs could preserve their binding affinity to their 
target antigens at fairly high concentrations of chaotropic agents (Dumoulin et al., 2002). Such 
unique feature might endow with ultimate promises for the production of new-fangled generation 
of oral antibody therapy. Not only the presence of intra-domain disulfide bonding between the 
CDRs is the reason behind their outstanding stability features, additionally is owed to their gifted 
ability to properly refold after enforced unfolding in case they are exposed to different thermal or 
chemical denaturation – e.g. high temperature, urea and guanidinium chloride (Dumoulin et al., 
2002; Ladenson et al., 2006). 
Solubility, VHHs can be concentrated up to 10-20 mg/mL without any significant 
aggregation, their superior solubility is partially dependent on the amino acid adaptations in their 
framework-2 which grant them more hydrophilic characteristics than other VHs (Muyldermans 
et al., 1994; Vu et al., 1997). The well-conserved hydrophobic VH residues which represent the 
binding site with the light variable domain VL are responsible for the aggregation tendency of 
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VHs when existing in aqueous solutions – i.e. to minimize the whole system free energy. In 
sharp contrast, VHHs’ residues are replaced with more hydrophilic ones (Maass et al., 2007). It 
is worth mentioning that these residues substitutions are encoded in the germline, and do not 
occur during somatic hyper-mutation (Nguyen et al., 1998). In addition to the residual 
substitution some other mechanisms are responsible for increasing the solubility of VHHs. For 
instance, the CDR3 loop folds over the hydrophobic region and shield it from aqueous 
environment (De Genst et al., 2006b). 
Numerous reports deep-rooted the fact that isolated VHHs from immunized libraries 
often have high binding affinity in the low nanomolar to sub-nanomolar ranges although it was 
thought that the lack of the VL chain may negatively affect the affinity of VHH in which the 
antigen-binding site is formed only by a single domain, thus it possesses only three CDR-loops 
for antigen binding. Consequently, it was expected that the paratope of VHHs would have a 
lower antigen-binding performance than that of conventional Antibodies (Cortez-Retamozo et 
al., 2004; Klooster et al., 2007). Moreover, their functional affinities – i.e. avidity, can be tailored 
for the favor of increasing its value to the optimal limit by constructing bi and multi-valence 
super molecules (Goldman et al., 2006; Verheesen et al., 2006). In general, VHHs’ libraries 
generated from immunized camelids retain full functional diversity, with high-affinity antigen 
binding domains that can be isolated through screening a limited number of clones from immune 
libraries without prior selection using display technologies (Harmsen et al., 2005; De Genst et 
al., 2010). 
 
2.3.5  Unique Features: Unconventional Epitope Recognition 
VHHs are the smallest known protein fragments with the ability to specifically recognize an 
antigen, these intact antigen-binding fragments measure about 2.4 nm in diameter and 4 nm 
height. These nanoscale characteristics that made Ablynx laboratories in Belgium call them 
Nanobodies®. The structural organization of the VHHs is comparable to that of the conventional 
VH with an Ig fold of two β sheets, one of four strands and one of five strands (Muyldermans et 
al., 2009). 
In conventional antibodies, the paratope – i.e. the antigen-binding site, is composed of 
both the heavy and light variable domains VH and VL (see Figure 1.6A). Despite the fact that, 
in quite few cases, the heavy chain alone can also bind some antigens (Utsumi & Karush, 1964). 
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The nature of such paratopes’ topography does not go well with the antigens’ epitopes with 
grooves or concaved structures. They are either a flat surface or a concave surface which is 
intimately similar to the cleft in the active sites of enzymes. As a result, the paratopes of 
conventional antibodies generally evade targeting clefts, the lock and key theory usually plays a 
critical role in many biological courses of actions. For example, almost all enzymatic reactions 
are based on the interactions between molecules (Lakowski et al., 1996). Hence, conventional 
antibodies are hardly ever recognized as competitive enzyme inhibitors or activators. 
The VHHs’ paratope is enlarged via extensions of CDR1 and CDR3 loops which are 
usually longer than that found in conventional antibodies. Additionally, the hypervariable loops 
of the VHH seem to vary substantially in conformation and length from the corresponding loops 
in VH of human and mouse (Nguyen et al., 2000; Decanniere et al., 2000). The longer CDR3 
region of the VHH possesses the extraordinary capacity to form finger-like extensions that 
protrude into antigen cavities, (see Figure 1.7), which will result in new antigen binding modes 
and put forward the VHHs to act as ideal enzyme inhibitors or activators (Wesolowski et al., 
2009). A considerable fraction of camelid VHHs, were developed against various enzymes, for 
instance, α-amylase, carbonic anhydrase and lysozyme, where they could act as target substrate 
and competitively inhibit the target enzymes (Lauwereys et al., 1998; De Genst et al., 2010).  
 
 
Figure 1.7. 3D-structures of Enzyme-Inhibiting sdAbs Derived from Camel HcAbs and Mouse 
Fv. The three CDR loops are color-coded as: CDR1 red, CDR2 green, CDR3 blue. A. Chicken 
lysozyme in complex with an inhibitory camel VHH. B: Chicken lysozyme in complex with the VL 
and VH domains of a mouse mAb (Wesolowski et al., 2009)  
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Persuasively, the small size and the longer CDR3 regions have the capacity to reach and 
recognize cryptic and hidden conformational epitopes that are otherwise inaccessible or not 
immunogenic for conventional antibodies, which makes them potent alternatives to conventional 
antibodies. Furthermore, VHHs still share the recognition of planar epitopes which are usually 
recognized by conventional antibodies (Muyldermans et al., 2009). A notable study by De Genst 
et al. in which a precise illustration strengthened by thorough crystallographic analysis could 
show the difference in epitopes recognized by conventional and VHH antibodies, they compared 
the crystal structures of conventional antibodies-lysozyme complexes with those of VHH-
lysozyme complexes (De Genst et al., 2006b). 
Collectively, in contrast to antigen-binding entities derived from classical antibodies, the 
use of recombinant VHH offers numerous advantages in biotechnology and medical applications 
due to some valuable intrinsic properties such as: 
 Smaller size allowing better penetration into dense tissues and neutralization of hidden 
antigen (Wernery et al., 1999; van Vliet et al., 2002; Stijlemans et al., 2004) or tumors 
(Cortez-Retamozo et al., 2004), 
 Higher thermo and chemical stability (Stok et al., 1999; Frenken et al., 2002), 
 Favorable structural features and their ability to form unique paratopes (De Genst et al., 
2006b; Wesolowski et al., 2009), 
 Superior specificity and affinity for the antigen due to the in vivo affinity maturation 
(antigen-specific VHHs can bind to their corresponding antigens with sub-nM affinities), 
 There are various efficient methods of VHH generation with a high yields and selection 
in a variety of expression systems (e.g. bacteria or yeasts) (de Geus et al., 2000; Harmsen 
& Haad, 2007), 
 A stringently monomeric behavior with no sign of spontaneous dimerisation, so that 
VHH samples are more homogeneous. 
Finally, the compulsory nature of VHHs makes them the best candidate to develop bi-and 
multi-specific antibodies or immuno-conjugates by fusing the genes of a VHH with another 
VHH, an enzyme and/or a toxin in one expression unit (Conrath et al., 2001b). Recently, a 
genuine method has been proposed by a group in the National Research Council of Canada, in 
order to obtain penta-valent VHH molecules that could increase their apparent affinity by 
introducing the avidity effect (Zhang et al., 2003). 
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2.4 Induction, Isolation, Expression and Purification of Camelidae VHH 
Recombinant DNA technology in addition to the vast development of various powerful selection 
strategies allowed the fast and efficient cloning of the harvested pool of VHHs from an 
immunized dromedary library and the selection of the antigen specific binders from this pool. 
Accordingly, it became feasible to have access to single domain antigen-binding entities.  
The most popular approach to select recombinant antigen-recognizing protein fragments 
– i.e. VHH binders, is the modified method of the biopanning of phage display libraries. Phage 
display is a technology in which genotype and phenotype of various types of bacteriophages are 
physically linked via inserting the gene of interest, which expresses a protein, within the 
phagemid technology for displaying it on the surface of a filamentous bacteriophage. Displaying 
a protein, such as VHH fragment, on the surface of a bacteriophage enables the utilization of 
these modified bacteriophages to select and enrich antigens specific binders through consecutive 
panning rounds (Ghahroudi et al., 1997; Verrips et al., 2000; Brissette & Goldstein, 2007). 
In an alternative strategy, Tanha et al., it was possible to generate a large single pot of 
naïve VHH library, cloned from a number of healthy llamas, from which binders were retrieved 
after multiple rounds of biopanning (Tanha et al., 2001). Furthermore, the framework-2 region of 
a human VH was adapted with the intention of mimicking the camelidae VHH, a process known 
as “camelization” (Davies & Riechmann, 1994). After that, the CDR3 codons of these camelized 
VH were then randomized and cloned in a phage display phagemid to retrieve binders from this 
obtained synthetic library (Davies & Riechmann, 1995). Noteworthy, the latter two strategies 
have the advantage that the immunization was totally avoided, however, the selected binders are 
usually of lower affinity and they need further mutagenesis steps to arrive at valuable kinetics. 
Therefore, it might be more convenient to use immune libraries to arrive at antigen-specific 
VHHs with appropriate characteristics for detailed applications (Tillib, 2011). 
 
2.4.1  Induction of HCAbs  
The Immunization procedures to elicit HCAbs in camelids are, in principle, similar to those in 
use to raise conventional antibodies in other animals (e.g. rabbit or goat immunization). In 
general, about five repetitive subcutaneous injections of antigen volume, of concentration about 
50-500 µg, mixed with equal volume of Freund or Gerbu adjuvant, are carried out in the course 
of 5-6 weeks. The initial immunization dose, as a rule, is using complete adjuvant and the rest of 
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booster doses use incomplete one (Conrath et al., 2001a). Worth mentioning, widely divergent 
antigens can be used all together for a single immunization (Lauwereys et al., 1998; Van der 
Linden et al., 2000). Likewise, subcutaneous injection of whole cells (108 cells in phosphate 
buffered saline PBS per shot) and other types of adjuvant is still successfully used to raise an 
HCAbs response (Maass et al., 2007). The bargain of selecting HCAbs from synthetic or naïve 
libraries is well-studied, it is confirmed that the HCAbs generated from immune libraries can 
recognize antigens with a higher affinity (i.e. binding affinity is from nanomolar to sub-
nanomolar range) since they undergo in vivo affinity maturation progression (Muyldermans et 
al., 2009; Ghassabeh et al., 2010). In spite of this limitation, the non-immune and synthetic 
libraries are still considered as attractive alternatives in a number of cases: (i) when only limited 
amount of antigen is available and/or (ii) in case of the antigen being toxic or non-immunogenic 
to camelids. 
 
2.4.2  Isolation of antigen specific VHHs 
Polyclonal, mono- and bi-valent, VHH antibodies can be isolated from the inborn HCAbs using 
primitive, simple and yet efficient proteolysis method. A prominent study by Lauwereys et al. 
could generate polyclonal monovalent VHHs containing α-amylase-specific binders by digesting 
the harvested HCAbs isotype IgG3 from Protein G chromatography with endo-Glu V8 protease. 
Afterward, the binders were separated from the cleaved Fc part by running chromatography on 
protein-A which is able to retain the Fc part. It is worth noting that, a considerable fraction of the 
dromedary VHHs still firmly bind to protein-A, which drastically affects the applicability of this 
method. In 1998, Muyldermans and his group at VUB laboratories could successfully obtain bi-
valent VHH (i.e. VHH2) by digesting the purified IgG3 isotype of HCAbs with pepsin, trypsin or 
papain (Lauwereys et al., 1998). These protease enzymes could cleave the hinge region primarily 
following the first disulfide bond linking the γ3 heavy chains, although, these methods can 
generate polyclonal VHHs from HCAbs IgG3 isotype, hitherto, the generation from IgG2 isotype 
is still calling for further development. 
Monoclonal antigen-specific VHHs of compulsory specificity can be easily identified via 
phage display method and can be produced in bacterial expression systems in relatively high 
amounts compared with the conventional antigen binding fragments Fabs (Nguyen et al., 2001; 
Olichon & Surrey, 2007). Isolation of VHHs includes the cloning of the full repertoire of VHH 
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genes extracted from the β-lymphocytes isolated from the peripheral blood (about 100 mL of 
whole blood) of immunized camel. Multiple sequential biochemical procedures are carried out: 
(i) total RNA isolation from white cells of blood, lymph node or spleen, (ii) complementary 
DNA (cDNA) synthesis, (iii) two-step polymerase chain reaction PCR using specific primers to 
amplify VHH sequences, (iv) constructing a VHH library of a satisfactory size. The construction 
of large immune libraries with the purpose of picking up the perfect antigen-specific binder has 
been proven redundant, this is elucidated by the fact that VHH unlike the conventional 
antibodies can bind to their target antigens by asset of only one single domain. Whereas, the 
antigen binding of the conventional forms usually depends on the presence of heavy and light 
chains. Accordingly, construction of conventional antibodies’ libraries should have room for all 
possible random association between heavy and light chains. Hence, it is highly favored to 
construct very large libraries to acquire all possible combinations of VH–VL chains, in order to 
find few of them which are similar to the original pairing scheme generated in vivo (Lauwereys 
et al., 1998; Alvarez-Reuda et al., 2007). Afterward, (v) the selection procedure and the 
identification of specific binders from VHHs libraries is done by the enrichment via phage 
display consecutive rounds of biopanning against the antigen of interest (Nguyen et al., 2001).  
 
Figure 1.8. Schematic Illustration of Phage Display Biopanning (Schirrmann et al., 2011)  
22 
 
Recently, it was suggested by Tillib et al. to use, in parallel, both conventional helper 
phage (M13KO7) and a modified helper phage which has an N-terminal deletion in the phage 
surface protein gIII which would greatly improve the selection procedure (Tillib et al., 2010). Up 
to date, all the available data obtained from diverse studies point out that the differential 
character of the selection of particular variants of VHH sequences in the process of biopanning 
procedure are independent of the number of panning rounds. Although one kind of clones can be 
successfully picked just right after the first panning round, yet, it can be lost during the following 
rounds. Nonetheless, other clones can be selected only after three or four panning rounds. In 
conclusion, it is important to set up the right design of the selection and monitoring procedure so 
as to improve the possibility of finding appropriate binders with explicit properties, such as the 
higher affinity, higher solubility and/or superior expression yield (Ghahroudi et al., 1997; 
Verrips et al., 2000; Tillib, 2011). 
 
2.4.3  Expression Systems: Factors Affecting the Yield 
The expression of VHHs in different expression systems has been well established, some studies 
could obtain high expression yields ranging from 5-10 mg/L in E. coli baffled shake flask 
cultures (Rahbarizadeh et al., 2005). Moreover, there are several reports of VHH production in 
plant and animal cells, for instance, tobacco and Chinese hamster ovary cells, respectively 
(Ismaili et al., 2007; Rajabi Bazl et al., 2007). VHH have also been produced in yeasts 
(Thomassen et al., 2002; Rahbarizadeh et al., 2006), although, most of such VHHs are (i) 
occasionally N-glycosylated (Frenken et al., 2000; Harmsen et al., 2005), which can severely 
affect their antigen binding properties (Van der Vaart et al., 2006), (ii) suffering from limited 
therapeutic application due to the increased immunogenicity resulting from the addition of yeast-
specific high-mannose oligosaccharides, and (iii) of short serum half-life, due to the binding of 
the N-glycosylated VHH to specific mannose receptors found in the reticuloendothelial system 
RES (Sethuraman & Stadheim, 2006).  
The production levels of VHHs in various microorganisms may vary radically among 
different clones such differences depend on (i) their specific sequences, (ii) the host and (iii) 
even nutrients in host growth media (Rahbarizadeh et al., 2006; Olichon et al., 2007; Van de 
Laar et al., 2007). As for sequences, it seems that sequence patterns of VHHs can affect their 
production level as follows: (a) production rate of conventional-like VHH is generally reduced in 
23 
 
yeast (Harmsen & Haad, 2007), (b) unpaired C-terminal cysteine residues result in a decrease in 
the expression level (Simmons et al., 2006), and (c) hydrophilic residues found in positions 
interacting with CH1which results in high expression levels (Harmsen & Haad, 2007). 
Regarding the host and nutritional media factors, VHHs’ production rate in baker’s yeast 
is related to the host growth rate (Thomassen et al., 2005), in addition, it can be increased by 
changing the medium (Van de Laar et al., 2007). Furthermore, supplementation of the medium 
has also been reported to improve VHHs production in Pichia pastoris (Rahbarizadeh et al., 
2006). In conclusion, the lack of post-translational modifications and the limitations of the 
folding machinery make the overexpression and production of conventional antibodies in 
bacteria and yeast almost impossible. Whereas, VHH are active without such modifications, and 
as being a single chain without the fragment crystallizable region Fc domain they are easily 
expressed in bacteria and yeast (Arbabi-Ghahroudi et al., 2005). It is worth mentioning that, the 
expression levels for camelid VHHs in some yeast, for instance,  Saccharomyces cerevisiae have 
been reported to be 100 mg/L from shaking flask and 1 g/L from a fed-batch fermentation 
(Frenken et al., 2000), with scalable expression yield reaching 1.3 kg from a 15 m3 fermentation 
(Thomassen et al., 2002). 
 
2.4.4  Purification Methods 
VHHs can be simply purified via various procedures. In 1999 Van der Linden et al. reported a 
simple ultrafiltration of the supernatant of yeast cultures with purity of about 80-90% just by 
passing through membranes with cut-off limits of 50 and 5 kDa in that order (Van der Linden et 
al., 1999). In addition to the ultrafiltration, the utilization of the intrinsic characteristic of 
subfamily III nanobodies® which bind to protein-A, many studies could purify nanobodies® by 
simple chromatography methods, however not all properly folded antibodies bind protein-A 
(Ghahroudi et al., 1997; Frenken et al., 2000). 
Recently, the possibility of including a C-terminal (His)6-tag paved the way for using the 
cost-effective chelating group-columns, nickel-nitrilotriacetic acid Ni-NTA products, a well-
known technique called immobilized metal affinity chromatography (IMAC), which frequently 
produce nanobodies® with satisfactory purities for most applications (Lauwereys et al., 1998; 
Alvarez-Reuda et al., 2007). Furthermore, an interesting study confirmed the practicability and 
reproducibility of a simple straightforward one-step heat treatment process to purify 
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Nanobodies® to a comparable level of purity to that obtained via IMAC; such swift and low-cost 
alternative to conventional chromatography process can still conserve the natural functionality of 
the produced antibodies (Olichon et al., 2007). 
  
2.5 Applications of Single-Domain Antibodies 
2.5.1  Medical applications: Emergence of Immunotherapy  
About a century ago, Paul Ehrlich announced that “since normal cells and cancerous cells differ 
in their staining properties, there should be a “magic bullet” to target only cancer cells”. This 
presumption did not come to realization until 1975 when Köhler and Milstein introduced the first 
mouse hybridoma technique (Köhler & Milstein, 1975) and, ever since, the production of 
monoclonal antibodies mAbs became a fact. In reality, the constant domains within the 
antibodies are not essentially involved in the antigen recognition mechanism. In view of that, a 
range of smaller antibody fragments which still preserve the antigen-binding affinity have been 
designed. Figure 1.9 illustrates various antibody fragments; mono- and bi-valent fragment 
antigen binding Fab, F(ab′)2, fragment variable Fv, single chain fragment variable scFv and 
eventually, the domain antibodies dAbs. Nevertheless, added to the technical difficulties, such 
as, spontaneous aggregation and poor expression yields in heterologous systems, which 
constantly face the generation of these antibody fragments from conventional antibodies; these 
produced biomolecules additionally suffer from pathologically relevant immune responses. The 
latter is responsible for their rapid clearance from the system and makes them unable to 
effectively interact with effector functions cells (Lee et al., 1998). 
 
Figure 1.9. Schematic Presentation of Various Antibody Fragments (Ghassabeh et al., 2010) 
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In 1980, Gabrielle Boulianne and his colleagues from Toronto University and Ontario 
cancer institute could design and produce the first chimeric antibodies (Boulianne et al., 1984), 
which was built from a variable antibody part from murine origin fused to the constant region of 
conventional human antibody. Noteworthy, after this primal experiment many attempts could 
effectively reduce the human anti-mouse antibody (HAMA) immune response (Hwang & Foote, 
2005). Loads of engineered designs of these murine antibodies were developed utilizing 
numerous ways for the sake of resolving the antigenicity concerns, from controlling the initial 
and terminal serum half lives to preventing the anti-globulin responses in order to fully exploit 
their immune effector functions.  
Humanization approach is the most common in which the CDRs regions are grafted into 
the human IgG backbone. In addition, the resurfacing approach shows enhanced results, in which 
the original human amino acids are only being replaced by the surface exposed murine residues 
(Zhang et al., 2005). On the other hand, this approach suffers from a significant reduction or 
complete loss of binding affinity since some of the residues in the removed framework are 
critical for maintaining the CDRs’ conformation (Chothia et al., 1989; Foote & Winter, 1992). 
Practically, the complex structure of full-length antibodies limits their use in only some of 
medical applications, such as imaging and active targeting. Financially, the production of mAbs 
also suffers from the very high costs which are increasingly becoming a burden for the 
healthcare sector. 
Nature has provided an inimitable answer, thanks to the exceptional repertoire of fully 
functional heavy chain only antibodies of the dromedaries and llamas. All of the previously 
conferred unique features of these antibody fragments imply that they will put forward 
remarkable promises to be exploited as robust reagents for presenting superior therapeutic and 
diagnostic applications as well as multipurpose biological properties. 
 
2.5.2  Medical Applications: Therapeutics 
Currently, there are various operational VHHs for different clinical settings, a notable study by 
Baral et al. demonstrated that the generation of VHH against the sleeping sickness inducing 
parasite Trypanosome rhodensiensis variance surface glycoprotein (VSG) fused to trypanolytic 
factor apolipoprotein L1 (APOL1) would establish a novel generation of anti-parasitic treatment 
strategies (Baral et al., 2006). In addition, toxin neutralizing VHHs have been generated against 
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lethal scorpion envenoming, these venom-neutralizing antibodies could successfully provide 
much higher efficacy and immunological advantages over conventional anti-venoms (Hmila et 
al., 2008; Hmila et al., 2010). Moreover, Tremblay and colleagues demonstrated that the VHHs 
have potential as components of therapeutic agents for reversal of botulism intoxication. The 
generated VHHs could act as neuronal cell intrabody binding agents and inhibitors of 
Clostridium botulinum neurotoxin proteases (Tremblay et al., 2011).  
VHHs have been used as an anti-pathogens either as a direct therapeutic agent such as the 
fused form used for the treatment of trypanosomiasis (Baral et al., 2006) or, indirectly, for 
preventing drug degradation by the pathogen (Conrath et al., 2001a). Moreover, VHH could 
reduce the morbidity of rotavirus induced diarrhea in mice (Van der Vaart et al., 2006). 
Furthermore, Antagonistic anti-TNF-β nanoantibodies established an outstanding therapeutic 
efficiency in a murine rheumatoid arthritis model. The therapeutic outcome was much higher 
than the effect of the conventional antibodies that are already in the use for the treatment of 
rheumatoid arthritis (Coppieters et al., 2006). Table 1.2 points up various selected therapeutic 
applications of VHHs (i.e. sdAbs) developed from different sources including immune, non-
immune and synthetic libraries. 
 
Table 1.2. sdAbs for Various Therapeutic Applications 
Target Source Application Reference 
FcgRIII (CD16) Immune Llama Cancer immunotherapy, 
Recruitment of NK cells 
(Behar et al., 2008) 
TNF-alpha Immune Llama Rheumatoid arthritis (Coppieters et al., 2006) 
HIV-1 Subtypes  Immune Llama Anti-viral therapy (Strokappe et al., 2012) 
Methotrexate Immune Llama Cancer therapy (Alvarez-Reuda et al., 2007) 
Hepatocyte 
growth factor 
Immune Llama Molecular cancer therapy 
drug discovery 
(Vosjan et al., 2012) 
Trypanosoma 
evansi 
Immune Dromedary Trypanosomiasis 
diagnosis and therapy 
(Saerens et al., 2008) 
Scorpion toxin Immune Dromedary Neutralization (Hmila et al., 2008; Hmila 
et al., 2010) 
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2.5.3  Medical Applications: Diagnostics  
In addition to therapeutics, VHHs were effectively used in developing a range of novel 
diagnostic applications. Such as, accurate determination of tumor epidermal growth factor 
receptor EGFR such as human epidermal growth factor receptor 2 (HER2), a tumor-associated 
molecule over expressed in about 30% of breast cancer patients. The detection was possible via 
imaging the radio labeled anti-HER2 VHH with 99mTc and 68Ga (Vaneycken et al., 2011; Vosjan 
et al., 2011). Noteworthy, the radio-labeling of VHHs facilitates the design of innovative 
biomolecules conjugates for drug discovery, immunotherapy and diagnosis of different 
biomarkers – positive tumors. As well, a notable study by Behar et al. demonstrated that high 
affinity sdAbs were successfully directed against nonconventional epitopes of human 
carcinoembryonic antigen (CEA), these antigen-binding sites totally differ from those defined by 
contemporary murine monoclonal antibodies (Behar et al., 2009). 
Chromobodies are fusion proteins that comprise an antigen binding VHH and a 
fluorescent protein. For instance, green fluorescent protein GFP, have been already generated 
making them proficient candidates for tracking the target antigen in vivo and ex vivo. This allows 
dynamic tracing and modulating the changes of target antigens at all stages of cell-cycle in living 
cells using various techniques, such as, the live cell microscopy (Rothbauer et al., 2006; 
Kirchhofer et al., 2010). In conclusion, such fluorescent-VHH conjugate show high potential for 
further theranostic applications. For example, the tracing of the fate of a certain antigen of 
interest (e.g. parasitic antigen) inside the living host, that possibly will pave the way for 
discovering a novel drug based on blocking a critical stage of the parasite life cycle. Finally, 
Table 1.3 points up different selected diagnostic applications of VHHs. 
Table 1.3. sdAbs for Various Diagnostic Applications 
Target Source Application Reference 
Dendritic cells Immune Camelid in vivo imaging (De Groeve et al., 2010) 
Taenia solium Immune Dromedary Cysticercosis  (Deckers et al., 2009) 
Trans-sialidase Immune Llama Trypanosomiasis  (Ratier et al., 2008) 
CEA Immune Llama Tumor targeting (Behar et al., 2009) 
HER2 Immune Llama in vivo imaging (Vaneycken et al., 2011) 
hPSA Immune Dromedary Cancer Diagnosis (Saerens et al., 2004) 
MUC1 Immune Camelid Tumor targeting (Rahbarizadeh et al., 2006) 
28 
 
3 Materials & Methods 
3.1 Materials 
3.1.1  Reagents, Buffers and Media 
Table 1.4. Reagents, Buffers and media utilized in this research (Vincke et al., 2012) 
Reagents, Buffers and Media Composition Supplier 
Dithiothreitol DTT 0.1 M DTT Sigma-Aldrich 
Complete Freund adjuvant1
 
 killed Mycobacterium tuberculosis 
non-metabolizable oils 
Sigma-Aldrich 
 
Incomplete Freund adjuvant non-metabolizable oils Sigma-Aldrich 
DiEthylPyroCarbonate 
Treated Water DEPC 
10 µL DEPC in 10 mL H2O 
incubate for 2 h at 37 ⁰C 
or overnight at room temp.  
autoclave 
Sigma-Aldrich 
 
Saline solution, 0.9% NaCl 9 g/L NaCl Merck 
TRIzol reagent kit  Invitrogen 
Chloroform/ Iso-amylalcohl 
(24/1) 
12 mL Chloroform 
0.5 mL Iso-amylalcohol 
Sigma-Aldrich 
 
Ethanol alcohol 100 % EtOH Sigma-Aldrich 
QIAquick Gel Extraction kit  Qiagen 
QIAquick PCR purification kit  Qiagen 
Sodium acetate (pH 5.2) 3 M Sodium Acetate 
adjust pH with 37% HCl 
Merck 
GenElute™ Plasmid Miniprep  Sigma-Aldrich 
GenElute™ PCR clean-up kit  Sigma-Aldrich 
LB medium (Luria-Bertani 
medium, pH 7.0) 
10 g/L Tryptone 
5 g/L Yeast extract 
10 g/L NaCl 
adjust to 1 L Milli-Q H2O 
autoclave 
Duschefa Biochemie 
Duschefa Biochemie 
Merck 
                                                 
1 Gerbu adjuvant (LQ#3000, GERBU Biotechnik GmbH, Heidelberg, Germany) can also be used. 
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Reagents, Buffers and Media Composition Supplier 
LB agar 15 g/L Microagar 
adjust to 1 L with Milli-Q H2O 
autoclave 
Duschefa Biochemie 
LB agar Amp/glucose LB agar 
100 µg/mL Amp 
1/10 20% glucose 
 
Duschefa Biochemie 
Duschefa Biochemie 
2xTY medium (pH 7.0) 16g/L Tryptone 
10 g/L Yeast extract 
5 g/L NaCl 
adjust to 1 L with Milli-Q H2O 
autoclave 
Duschefa Biochemie 
Duschefa Biochemie 
Merck 
2xTY Amp/Kan 2xTY medium 
100 µg/mL Amp 
70 µg/mL Kan 
 
Duschefa Biochemie 
Duschefa Biochemie 
TB (Terrific Broth) 12 g/L Tryptone 
24 g/L Yeast extract 
2.31 g/L KH2PO4 
12.54 g/L K2HPO4 
4 mL/L Glycerol 
adjust to 1 L with Milli-Q H2O 
autoclave 
Duschefa Biochemie 
Duschefa Biochemie 
Merck 
Merck 
Duschefa Biochemie 
SOB medium 20 g Tryptone 
5 g Yeast extract 
0,5 g NaCl 
1,86 g KCl 
adjust to 1 L with Milli-Q H2O 
autoclave 
Duschefa Biochemie 
Duschefa Biochemie 
Merck 
Merck 
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Reagents, Buffers and Media Composition Supplier 
SOC medium 25 mL SOB 
500 µL 1M MgSO4 
125 µL 2M MgCl2 
 
Merck 
Merck 
PBS (Phosphate Buffered 
Saline, pH 7.4) 
136 mM NaCl 
2.6 mM KCl 
10 mM Na2HPO4 
1.5 mM NaH2PO4 
Merck 
Merck 
Merck 
Merck 
PBS-milk PBS + 2 % milk powder Nestlé 
PBS/Tween PBST PBS + 0.05 % (v/v) Tween-20 Sigma-Aldrich 
Tris-HCl (pH 8.0) 1 M Trizma® base 
adjust pH with 37% HCl 
adjust to 1 L with Milli-Q H2O 
Sigma-Aldrich 
TES (Tris-EDTA-sucrose) pH 
8.0 
0.2 M Tris-HCl (pH 8.0) 
0.5 mM EDTA 
0.5 M Sucrose 
 
Merck 
Duschefa Biochemie 
10x TBE (Tris-borate-EDTA 
buffer) 
108 g Trizma® base 
55 g Boric acid 
9.3 g EDTA 
adjust to 1 L with Milli-Q H2O 
Sigma-Aldrich 
Merck 
Merck 
PEG/NaCl solution 20 % w/v PEG-6000 
2.5 M NaCl 
adjust to 1 L with Milli-Q H2O 
autoclave 
Duschefa Biochemie 
Fisher Scientific 
Ampicillin (Amp 100 mg/mL 
stock solution) 
1 g Amp 
10 mL 70 % ethanol 
sterilization by filtration through  
0.22 µm Express™ Plus-filter 
Duschefa Biochemie 
Fisher Scientific 
Millipore 
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Reagents, Buffers and Media Composition Supplier 
Kanamycin (Kan 70 mg/mL) 0.7 g Kan 
10 mL Milli-Q H2O 
sterilization by filtration through  
0.22 µm Express™ Plus-filter 
Duschefa Biochemie 
 
Millipore 
IPTG (Isopropyl-β-D 
thiogalactopyranoside) 
1 M IPTG 
Milli-Q H2O 
sterilization by filtration through  
0.22 µm Express™ Plus-filter 
Duschefa Biochemie 
 
Millipore 
DNA loading buffer 0.25 % Bromophenol blue 
0.25 % Xyleen cyanol FF 
15 % Ficoll™ PM400 
84.5 % Milli-Q H2O 
Merck 
Merck 
Amersham 
Bioscience 
Ethidium bromide (EtBr 
10mg/mL) 
1g EtBr 
dissolve in 100 mL of Milli-Q H2O 
Merck 
20x MES buffer (pH 8.3) 195.2 g MES (2-(N-morpholino) 
ethane sulfonic acid) 
121.2 g Trizma® base 
6 g EDTA 
20 g SDS 
adjust to 1 L with H2O 
 
Sigma-Aldrich 
Sigma-Aldrich 
Merck 
Duschefa Biochemie 
SDS-PAGE Staining solution 0.125 g Coomassie® Brilliant Blue 
R250 
50% Methanol 
10% Acetic acid 
adjust to 1 L with H2O 
Fluka 
 
Lamers & Pleuger 
Vel 
SDS-PAGE Destaining 
solution 
10% Acetic acid 
40% Methanol 
adjust to 1 L with H2O 
Vel 
Lamers & Pleuger 
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Reagents, Buffers and Media Composition Supplier 
AP-blot buffer (pH 9.8) 1 M Diethanolamine 
1 mM MgSO4 
 
Merck 
Trimethylamine (TEA) 70 µL TEA 
5 mL Milli-Q H2O 
Sigma-Aldrich 
0.5M Imidazole in PBS 3.5 g Imidazole 
dissolve in 100 mL PBS 
adjust pH to 7.5 with 37% HCl with 
sterilization by filtration through  
0.22 µm Express™ Plus-filter 
Sigma-Aldrich 
 
Merck 
Millipore 
HEPES buffer (pH 7.0) 1 mM HEPES 
Autoclave 
Sigma-Aldrich 
10X Buffer H 500 mM Tris-HCl, pH 7.5 
100 mM MgCl2 
10 mM Dithiothreitol (DTT) 
1000 mM NaCl 
Roche 
10X Buffer R  Fermentas 
 
3.1.2  Equipments and Consumables 
Table 1.5. Equipments and Consumables used in this research (Vincke et al., 2012) 
Equipment/Consumable  Supplier 
Lab centrifuge with swing-out rotor  Eppendorf  
Separation tube for whole blood lymphocytes and peripheral  
monocellular cells Leucosep™  
Greiner Bio-One 
Falcon tubes  BD Falcon™ 
RNase-free tubes and Micropipette tips Eppendorf 
Pasteur glass pipette and Ball to aspirate  
Water bath and heating block  
Thermocycler BioRad 
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Equipment/Consumable  Supplier 
Agarose gel electrophoresis BioRad 
UV trans-illuminator  
Vortex  
Microcentrifuge  
Nanodrop® spectrophotometer Thermo Scientific 
Shaker incubator  
Gene Pulser Electroporation instrument BioRad 
Electroporation cuvettes BioRad 
Cell scraper BD Biosciences 
Large square Petri dishes (243 x 243 mm)  
Glass beads, average size 
(0.25-0.35 cm diameter) 
E&R Chemicals and 
equipments 
Maxisorb 96-well microtiter plate NUNC 
Round bottom 96-well microtiter plate BD Biosciences 
Microtiter plate reader  
Gel-filtration column HiLoad S75 (16/60) On ÅKTA Express GE Healthcare 
HIS-Select® Nickel Affinity Gel Sigma-Aldrich 
Vivaspin-15 (MWCO 5,000 PES) Vivasciences-Sartorius 
PD-10 columns GE Healthcare 
 
3.1.3  Bacterial Strain 
Two bacterial Escherichia coli (E. coli) strains were used in this study:  
(i) E. coli TG1 strain for biopanning and the selection of antigen specific VHH 
• E. coli TG1: 
K12, Δ(lac-pro), supE, this, hsdD5/F′traD36, proA+B+, lacq, lacZΔM15 
(ii) E. coli WK6 strain for the Nanobodies® expression, they are su- which make them 
unable to read-through the amber stop codon. 
• E. coli WK6: 
K12, Δ(lac-proAB) galE, StrA/F′, laclq, lacZΔM15, proA+B+ 
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3.1.4  Plasmids: pMECS 
The pMECS is a pUC derived phagemid vector used for phage display, it is designed for 
efficient production of soluble Nanobodies® and the selected VHH coding genes are cloned 
between a pelB leader signal sequence, which transports the VHH to the bacterial periplasm. The 
phagemid has an F1 origin of replication, upstream of a hemagglutinin tag (HA-tag), a C-
terminal hexahistidine-tail (His6) and gene III from M13 bacteriophage. The pMECS vector 
contains an ampiciline resistance gene as well. Figure 1.10 displays the pMECS gene map.  
 
Figure 1.10. Schematic Representation of pMECS Vector (Florea, 2011) 
The relevant genes, restriction enzymes and tagging sites are given: 
• Multiple cloning sites. 
• E coli. Plac promoter: Isopropyl-β-D-thiogalacto-pyranoside (IPTG) inducible. 
• Pectate lyase B (pelB) signal sequence: bacterial Sec-dependent translocation signal 
sequence transports the unfolded protein (Nanobody®) into the periplasm. 
• Gene III (g III): encodes the phage coat protein (pIII) of phage M13. The protein of 
interest (the Nanobody®) to be displayed is fussed to pIII and that will allow the VHH to 
be displayed together with pIII on the phage coat for panning. An amber stop codon 
(TAG) is located between the HA-tag and gIII, which is partially suppressed in a 
suppressor strain such as E. coli TG1. 
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• Polyhistidine tag (His6): sequence located downstream of the VHH gene. It is used for 
ease of purification on immobilized metal affinity chromatography (IMAC). 
3.1.5  Bacteriophage 
M13KO7 helper phage (> 1011 plaque forming units/mL), in-house prepared, is an M13 
derivative filamentous bacteriophage. The native particle is a thin, cylindrical shape usually 900 
nm long and 6–7 nm in diameter (Carmen & Jermutus, 2002). It carries the mutation Met40Ile in 
geneII, with the origin of replication from P15A and the kanamycin (Kan) resistance gene from 
Tn903 both inserted within the M13 origin of replication. M13KO7 is capable to replicate in the 
absence of phagemid DNA. Figure 1.11 illustrates the schematic diagram of the M13 phage 
vector. While, in the presence of a phagemid bearing a wild-type M13 of f1 origin a single-
stranded phagemid is preferentially packaged and secreted into the culture medium. 
 
Figure 1.11. Schematic Diagram of the M13K07 Phage Display Vector Used for Cloning 
Libraries of Immunized Camelids. VHH are expressed on the phage coatimmunized camelids, 
afterward the inserted VHHs codons are expressed on the phage coat as fusion to the gIII 
protein (Wesolowski et al., 2009)  
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3.1.6  Primers 
Table 1.6. All used PCR primers utilized for the amplification and sequencing of the VHH genes. 
Restriction enzyme sites are underlined (Arbabi-Ghahroudi et al., 1997) 
Primers  Sequence (5'- 3') 
A6E  GATGTGCAGCTGCAGGAGTCTGGRGGAGG 
                                PstI 
Call001(20 uM)             GTCCTGGCTGCTCTTCTACAAGG 
 
Call002 (20 uM)  GGTACGTGCTGTTGAACTGTTCC  
    
FP  TTCCCAGTCACGAC  
    
RP  CACACAGGAAACAGCTATGAC  
    
MP57  TTATGCTTCCGGCTCGTATG  
    
GIII  CCACAGACAGCCCTCATAG  
    
Primer38  GGACTAGTGCGGCCGCTGGAGACGGTGACCTGGGT  
                               NotI                                BstEII  
    
 
3.1.7  Enzymes 
Table 1.7. All used restriction enzymes utilized for the cloning of the VHH fragments. Restriction 
enzyme sites are illustrated (Vincke et al., 2012) 
Restriction enzymes Cutting Site     Supplier 
Eco91I (10 u/µL) 5’…G^GTNACC…3’     Fermentas   
 3’…CCANTG^G…5’  
 
Xba1 (10 u/µL) 
 
5’…C^TCGAG…3’ 
 
    Fermentas   
 3’…GAGCT^C…5’  
 
NotI (10 u/µL) 
 
5’…GC^GGCCGC…3’ 
 
    Roche   
 3’…CGCCGG^CG…5’  
 
PstI (10 u/µL) 
 
5’…CT GCA^G…3’ 
 
Roche 
 3’…GDACGTC…5’  
 
ExoI (20 u/µL) 
 
Catalyzes the removal of nucleotides from 
single-stranded DNA in the 3' to 5' direction 
 
Fermentas 
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Table 1.8. PCR reagents, DNA polymerase and other enzymes utilized for the cloning of the 
VHH fragments 
PCR reagents, DNA Polymerase and other enzymes Supplier 
Oligo-dNT12-18 Invitrogen 
dNTP mix (10 mM each) Invitrogen 
Superscript II First-Strand Synthesis System, 
for Reverse Transcriptase RT-PCR(200 u/µL) 
Fermentas 
 
Ribolock ™ RNase Inhibitor, 
Human Placental RNAse Inhibitor HPRI (40 u/µL) 
Fermentas 
FastStart Taq polymerase (5 u/µL) Roche 
Taq DNA polymerase Sigma-Aldrich 
T4 DNA ligase (5 u/µL) Fermentas 
Shrimp alkaline phosphatase (SAP, 1 u/µL) Fermentas 
DNA smart ladder Eurogenetec 
Hinf (10 u/µL) Fermentas 
ExoSAP-IT Affymetrix 
 
3.1.8  Antibodies 
Table 1.9. Antibodies utilized for IgG ELISA, PE ELISA and Nanobodies® selection 
Antibody Supplier 
Rabbit anti-camel polyclonal Ab Sigma-Aldrich 
Rabbit anti-VHH polyclonal Ab Developed in house 
Goat anti-rabbit IgG alkaline phosphatase conjugate Sigma-Aldrich 
Mouse anti-M13 horse radish peroxidase conjugate Amersham Biosciences 
Mouse anti-His-tag mAb Abd Serotec 
Goat anti-Mouse IgG Amersham Biosciences 
 
3.1.9  Animal and Materials used for Immunization and Nanobodies® Selection 
 Young adult camel (well behaved2
 Native Schistosoma mansoni Cathepsin-B (SmCB) Antigen, 0.5-1mg. 
, three years old, 250-275 kg male). 
                                                 
2 The behavior of Camel is considered as a general indicator of its health status (Wernery et al., 1999) 
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 Execratory Secretory Schistosoma mansoni (SmES) Antigen, 0.5-1 mg. 
Both proteins are cooperatively provided by Dr. Ibrahim Rabee, Immunology Department, 
Theodor Bilharz Research Institute TBRI, Giza, Egypt.  
Noteworthy, the used antigens are preferred to be well folded/structured proteins. 
Nevertheless, the proteins used for immunization can be contaminated with other neither non 
proteases nor toxic antigens, however, it is highly recommended to use high purity proteins for 
biopanning and binders identification (typically recombinant proteins). 
 
3.2 Methods 
In this section, a detailed step-by-step description of the entire processes of developing of the 
variable domain of the heavy chain of the heavy-chain antibodies VHH, also known as single-
domain anti-bodies (sdAbs) and Nanobodies® (Nbs). Part of the steps and methods will not be 
fully described, those should be carried out as per their manufacturers and suppliers described. 
Moreover, other parts will be described according to the Department of Molecular and Cellular 
Interactions Laboratories’ (CMIM Lab), Flanders Interuniversity institute for Biotechnology 
(VIB),Vrije Universiteit Brussel (VUB) in-house protocols. The extent of description will start 
with a camel’s immunization step, going through the expression and purification of the enriched 
antigen specific binders. Finally, brief estimation of the binding affinity properties of the 
produced sdAbs will be addressed as well.  
 
3.2.1 Camel’s Immunization 
A young adult male, well behaved with normal appetite, three years old healthy camel was 
carefully selected to immunize. The dromedary camel was subcutaneously immunized multiple 
times with the antigens mixed with (a) Freund complete adjuvant (for first injection) and (b) 
Freund incomplete adjuvant (for booster injections). The presence of adjuvant is mainly to 
enhance the immune response of the animal in order to increase the titer of the B lymphocyte 
cells. After proper amount and doses of immunization doses over an optimum period of time it is 
highly anticipated to have an affinity-matured antigen-specific HCAbs expressed on the B cells. 
The immunization protocol adapted in this work tones with the VIB in-house regular 
protocol, and other previously reported standard immunization protocols of camels (Conrath et 
al., 2001a). 
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Procedure 
1. The adjuvant was stored and handled as described by the manufacturer’s product 
information guide. 
2. Just before immunization, one aliquot of each -20 ⁰C frozen antigens was thawed and 
mixed via vigorous vortex with an equal volume of adjuvant until a thick emulsion 
was formed. 
Critical Step: While using complete Freund’s adjuvant for first injection, vortex or shake 
well to resuspend the Mycobacterium.   
3. The emulsion was transferred to a syringe with an appropriately sized needle and 
injected subcutaneously. 
4. The immunization steps were designed as follow: 
 
Table 1.10. Camel Immunization Steps 
Injection Time Interval Adjuvant Volume Antigen Volume (1 mg/mL) 
First Injection Day 0 250 µL 250 µL  
1st Boost One Week 250 µL 250 µL 
2nd Boost Two Weeks 200 µL 200 µL 
3rd Boost Three Weeks 150 µL 150 µL 
4th Boost Four Weeks 100 µL 100 µL 
5th Boost Five Weeks   50 µL   50 µL 
6th Boost Six Weeks   50 µL   50 µL 
 
Note: The gradual tapering of the injected doses’ concentration was intended to enrich 
only the B cells which express HCAbs of high affinity. 
Caution: Despite the fact that camels are not commonly considered as experimental 
animals, general regulations concerning to animal welfare, protection and good experimental 
practices were taken into consideration. During the immunization schedule routine checkups 
were carried out twice a week to insure the proper supply of nutrition for camel in order to 
maintain good health, in addition, some developed local tumefactions were watchfully treated. 
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3.2.2 Preparation of Peripheral Blood Lymphocytes and Extraction of Total RNA 
Procedure 
1. Approximately 100 mL of peripheral blood was collected four days after the last 
boost on an anticoagulant EDTA (2g EDTA/100 mL blood). 
2. The anti-coagulated blood was diluted with an equal volume of 0.9% NaCl. 
3. Carefully, about 30 mL of diluted blood was transferred into each Leucosep™ tube. 
4. The tubes were centrifuged at room temperature for 10 min at 1000 g. 
Critical Step: The centrifugation must be carried out using a swing-out rotor, while both 
acceleration and deceleration breaks were disabled. 
5. The plasma layer formed in the topmost was carefully removed via Pasteur pipette as 
much as possible in order to minimize the contamination of the underneath peripheral 
blood lymphocytes PBLs and transferred to another tubes for further IgGs 
purification and for evaluation of immune response against antigens. 
6. All the procedures followed the recommended experimental practice of the 
manufacturer’s instruction manual, as illustrated in Figure 1.12-1.15. 
 
Figure 1.12. Filling with diluted blood before centrifugation. The anti-coagulated and diluted 
whole blood samples were carefully transferred to each Leucosep™ tube. 
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Figure 1.13. Layers Separation after Centrifugation. After centrifugation the sequence of layers 
occurs as follows (a) plasma; (b) enriched cell fraction (white ring interphase of lymphocytes 
and PBMC’s);  (c) separation medium; (d) porous frit barrier; (e) separation medium, and  
finally (f) pellet (erythrocytes and granulocytes). 
             
                    
 
Caution: All blood samples must be handled with care in accordance with the policies 
and procedures of working facility. In case of any accidental exposure or contamination with 
blood an appropriate medical treatment must be instantly initiated. 
Figure 1.14. Harvest PBLs and 
PBMCs by means of a Pasteur pipette.  
 
Figure 1.15. Transferring plasma to  
other tubes for further experiments.     
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7. The collected PBLs volume was divided into two fresh centrifuge tubes, afterward 
they were diluted and washed twice with at least 10 times volume of phosphate 
buffered solution PBS and the tubes were centrifuged at 4 ⁰C for 10 min at 250 g. 
8. The supernatants were decanted, each cell pellet was gently re-suspended in about 5 
mL PBS, all the suspension were collected in one tube, afterward, the PBLs washed 
two more times via centrifugation as described above (see Method 3.2.2. 7). 
9.  Total RNA was isolated from the prepared PBLs using TRIzol reagent kit, where all 
the procedures followed the technical instruction manual of supplier.  
10. The RNA concentration was measured by UV-spectrophotometer (i.e. OD260nm of 1 
approximately corresponds to 40 µg RNA/mL).     
Pause Point: The isolated RNA can be used immediately to synthesize the first 
complementary DNA strand (cDNA) or can be stored at -80 ⁰C. 
 
3.2.3 Preparation of First Strand cDNA from RNA 
Under appropriate sterilization conditions, RNAse free materials and laminar air flow, the 
extracted total RNA is used as a template to prepare cDNA using commercial reagent s. 
Procedure 
1. The secondary structure of the RNA was destabilized by incubating the following 
mixture for 10 min at 70 ⁰C: 
 Total RNA    10 µL (≈ 40 µg) 
 Oligo-dT12-18 primer   11 µL (5.5 µg) 
 DEPC-H2O             105.5 µL 
 Total volume                                     126.5 µL (premix for 5 tubes x 23 µL) 
2. The mixture was placed immediately on ice for 5 min, then added to it the following 
mixture: 
 5x 1st strand buffer          44 µL 
 0.1 M DTT          22 µL 
 dNTPs (10 mM each)         11 µL 
 HPRI (40 units/µL)        5.5 µL 
 Superscript™ II Reverse Transcriptase (200 units/µL)     11 µL 
 Total volume       93.5 µL 
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3. In a spinning rotor the mixture was well-mixed and gently centrifuged, the volume 
was divided over 5 tubes (17 µL each) then incubate the mixture as follows: 
 42 ⁰C  for  1 h   (annealing time) 
 45 ⁰C for 20 min  (cDNA synthesis) 
 70 ⁰C for  15 min (to inactivate the reverse transcriptase enzyme) 
 End cycle: 4 ⁰C 
Pause Point: After the incubation sequence, all the mixture tubes are collected and either 
stored at -20 ⁰C or, straight away, used to amplify the VHH sequences. 
  
3.2.4  Nested Polymerase Chain Reaction for VHH Sequences’ Amplification 
The amplification if the VHH sequences’ was carried out through two consequent PCR runs. The 
first run will yield two distinctive groups of amplicons: group-1, molecular weight 0.7 kb and 
group-2, molecular weight 0.9 kb. The first group originated from the HCAbs-encoding mRNA 
(i.e. VHH-hinge-CH2), while, the heavier second group represents the VH-CH1-hinge-CH2. The 
0.7 kb fragment is purified from the agarose gel and used as a template for a nested PCR 
amplification process specific to VHH-only sequences. Corresponding restriction enzymes are 
introduced for further cloning into the phage display vector (pMECS, see Figure 1.10). 
Procedure 
1. Premix volume for about 24 tubes was prepared as follows: 
 H2O            954 µL 
 10x PCR buffer          120 µL 
 dNTPs (10 mM each)           24 µL 
 20 µM call 01 primer           24 µL 
 20 µM call 02 primer           24 µL 
 Fast Start Taq DNA Polymerase           6 µL 
 Total volume                   1152 µL 
2. The above mixture was divided over 24 tubes from Westburg strips (48 µL/tube), and 
the cDNA template was added as follows: 
 Set 0: 2 tubes, each tube 0.5 µL of 2-fold diluted cDNA 
 Set 1: 4 tubes, each tube 1.0 µL of 2-fold diluted cDNA 
 Set 2: 4 tubes, each tube 2.0 µL of 2-fold diluted cDNA 
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 Set 3: 4 tubes, each tube 2.0 µL of non-diluted cDNA 
 Set 4: 4 tubes, each tube 3.0 µL of non-diluted cDNA 
 Set 5: 5 tubes, each tube 4.0 µL of non-diluted cDNA 
 Negative control: no template added, only 48 µL premix 
3. PCR runs was executed as per the following design: 
 Lid temperature:  105 ⁰C 
 Pre-cycle:    95 ⁰C for 7 min (to activate the polymerase) 
 Thirty one cycle as follows: 
• 94 ⁰C  for  1 min (denaturation) 
• 55 ⁰C for 1 min (annealing) 
• 72 ⁰C for 1 min (extension) 
 Post-cycle:    72 ⁰C for 10 min (final extension) 
 End cycle:                          4 ⁰C 
4. The PCR products of each set were pooled, then 8 µL of each set was applied on a 
1% (w/v) agarose gel in TBE buffer and EtBr. In addition, 5 µL of DNA smart ladder 
was used in an adjacent lane. 
5. After running the gel at 125 V for 35 min, the DNA bands were visualized under a 
UV trans-illuminator, where 2-3 fragments are expected, one bigger VH fragment 
(about 900-1000 bp), and 1-2 shorter bands (≈ 700 bp) for VHH. 
6. All the sets in which bands around 700 bp were present and their related PCR tubes 
were pooled together, then all of the pooled volume was applied on  a mini-gel cast 
with one wide slot of 1% (w/v) agarose gel and the gel was run ( see above).  
Pause Point: the pooled 1st PCR products can be stored at -20 ⁰C. 
7. After electrophoresis, the agarose gel was put on a well-cleaned UV trans-illuminator 
for cutting out the specific PCR band (≈ 700 bp) with a sterile blade.  
Critical Step: the exposure time to UV must be minimized as much as possible to prevent 
DNA damage (e.g. pyrimidine dimer formation) that inhibits further PCR amplification. 
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8. The extracted fragment was weighed then purified from the gel block using the 
QIAquick Gel Extraction kit. Finally, the purified DNA was eluted in 100 µL H2O, 
and its concentration was measured at OD260nm using Nanodrop spectrophotometer. 
Pause Point: the eluted DNA products can be stored at -20 ⁰C, or immediately used as 
template for the subsequent step (i.e. nested PCR). 
9. The second step of the nested PCR was carried out by preparing a premix volume 
sufficient for 10 PCR tubes, as follows: 
 DEPC water          358 µL 
 10x PCR buffer            45 µL 
 dNTPs (10 mM each)             9 µL 
 20 µM VHHBACK primer            9 µL 
 20 µM PMCF primer             9 µL 
 Fast Start Taq DNA Polymerase      2.25 µL 
 Total volume          432 µL 
10. The premix volume kept on ice while dividing equally onto the Westburg strips tubes 
(≈ 40 µL each), after that, the cDNA template was added as follows: 
 Set 1: 2 tubes, each tube 1.0 µL of 1st PCR purified DNA 
 Set 2: 2 tubes, each tube 2.0 µL of 1st PCR purified DNA 
 Set 3: 3 tubes, each tube 3.0 µL of 1st PCR purified DNA 
 Negative control: no template added 
11. PCR runs was executed as per the following design: 
 Lid temperature:  105 ⁰C 
 Pre-cycle:    95 ⁰C for 7 min (to activate the polymerase) 
 Seventeen cycle as follows: 
• 94 ⁰C  for  1 min (denaturation) 
• 55 ⁰C for 1 min (annealing) 
• 72 ⁰C for 1 min (extension) 
 Post-cycle:    72 ⁰C for 10 min (final extension) 
 End cycle:                           4 ⁰C 
12. From each set, 8 µL was applied on a 1% (w/v) agarose gel in TBE buffer and EtBr. 
In addition, 5 µL of DNA smart ladder was used in an adjacent lane. 
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13. After running the gel at 125 V for 35 min, the DNA bands are visualized under a UV 
trans-illuminator, where the presence of 400 bp bands are anticipated, which 
represents the size of VHHs. 
14. All successful PCR sets are pooled together, and the amplified DNA was purified 
using QIAquick PCR purification kit. Finally the purified DNA was eluted in about 
200 µL H2O and the concentration was measured at OD260nm using Nanodrop 
spectrophotometer. 
Pause Point: the 2nd PCR eluted DNA products can be stored at -20 ⁰C, or immediately 
used for the subsequent steps. 
 
3.2.5  Digestion of VHHs and pMECS and Ligating Same 
Procedure 
1. The 2nd PCR product was digested overnight at 37 ⁰C, as follows: 
 H2O            250 µL 
 2nd PCR product (≈ 10 µg)           200 µL 
 10x H buffer            50 µL 
 PstI (40 units/µL)             5 µL 
 NotI (40 units/µL)             5 µL 
 Total volume          510 µL 
2. In parallel, the pMECS vector was digested overnight at 37 ⁰C, as follows: 
 H2O            680 µL 
 pMECS vector (≈ 500 ng/µL)         120 µL 
 10x H buffer            90 µL 
 PstI (40 units/µL)             9 µL 
 NotI (40 units/µL)             9 µL 
 Total volume          900 µL 
3. The restriction enzyme digested 2nd PCR product was purified with QIAquick PCR 
purification kit protocol, using 3 columns. Finally, the purified VHHs’ DNA was 
eluted in 180 µL H2O. 
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4. The eluted DNA is digested again overnight at 37 ⁰C, as follows:  
 Digested PCR product         176 µL 
 10x H buffer            20 µL 
 PstI (40 units/µL)             2 µL 
 NotI (40 units/µL)             2 µL 
 Total volume          200 µL 
5. The restriction enzyme digested pMECS vector was purified with QIAquick PCR 
purification kit protocol, using 6 columns. Finally, the purified digested vector was 
eluted in 540 µL H2O. 
6. The eluted pMECS vector is digested again overnight at 37 ⁰C, as follows:  
 Digested pMECS vector         538 µL 
 10x H buffer            60 µL 
 PstI (40 units/µL)             2 µL 
 NotI (40 units/µL)             2 µL 
 Total volume          600 µL 
7. Again, the restriction enzyme digested 2nd PCR product was purified with QIAquick 
PCR purification kit protocol, using 2 columns. Finally, the purified VHHs’ DNA 
was eluted in 100 µL H2O and the concentration was measured at 260 nm using 
Nanodrop spectrophotometer. Finally, stored at -20 ⁰C. 
8. Then, 2 µL of XbaI (40 units/µL) was added to the pMECS secondary digestion 
mixture and incubated for 1 hour at 37 ⁰C. The restriction enzyme digested pMECS 
vector was then purified with QIAquick PCR purification kit protocol, using 4 
columns, where the purified vector was eluted in 300 µL H2O (75 µL H2O each), the 
concentration was measured at 260 nm using Nanodrop spectrophotometer. Finally, 
stored at -20 ⁰C. 
Critical Step: Some DNA molecules are only cleaved by single enzyme, the 
additional XbaI digestion step for the vector will prevent the self ligation of these 
molecules. 
Check Point: In order to check the digestion efficiency, 0.5 and 1.0 µL of both 2nd 
PCR product and pMECS vector were applied on a 1% agarose gel in TBE and EtBr 
and run at 125 V for 30 min. 
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9. Three different concentrations of the pMECS vector and insert were prepared in order 
to get the optimal ratio, as follows: 
 Tube 1 Tube 2 Tube 3 
pMECS Vector 4.4 µg 4.4 µg 4.4 µg 
Insert – 2nd PCR 1.7 µg 3.4 µg 5.1 µg 
10. To each of the above tubes, 2.5 µL T4 DNA ligase (5 units/µL) and 15 µL 10x 
ligation buffer were added, then the final volume was brought up to 150 µL with 
H2O, the mixture was gently mixed and span in microcentrifuge, and incubated at 16 
⁰C for 4 hours. 
11. After incubation, 25 µL of the following mixture was added to each tube as follows: 
 H2O                       xx µL  
 10x ligation buffer          8.5 µL 
 pMECS (4.4 µg)            xx µL 
 Insert - 2nd PCR (8.4 µg)          xx µL 
 T4 DNA ligase (5 units/µL)            3 µL 
 Total volume            85 µL 
Caution: The (xx) volume of the vector and the insert were carefully calculated in order 
to give a final concentration of about 4.4 µg and 8.4 µg respectively. The final volume 
was adjusted with H2O. 
12. The mixture was gently mixed and span in microcentrifuge, and incubated overnight 
at 16 ⁰C. 
13. Cleaning the ligation reaction was done as follows: 
13.1. The ligation reaction was heated for at 65 ⁰C for 10 min, so as to inactivate the 
ligase enzyme. 
13.2.  All the three tubes were pooled, and then added 100 µL of H2O to a final 
volume of about 610 µL. 
13.3. An equal volume of TE-saturated phenol (i.e. ≈ 610  µL from the lower phase) 
was added, vortex and centrifuged at 18,000 g for 10 min to separate the phases. 
13.4. The upper aqueous phase was transferred to a fresh eppendorf tube, then an 
equal volume of Chloroform/Isoamyl alcohol (24/1 ratio) was added, vortex and 
centrifuged at 18,000 g for 10 min to separate the phases. 
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13.5. Again, the upper aqueous phase was transferred to a fresh eppendorf tube, then 
added 1/10th volume of 3 M sodium acetate (pH 5.2), mixed via in/out pipetting. 
13.6. Added three volumes of absolute ethanol (100% EtOH), then mixed via 
inverting the tubes, and then incubated at -80 ⁰C for 30 min. 
13.7. The content was centrifuged at 18,000 g for 20 min, the upper liquid was 
carefully removed without disturbing the “invisible” DNA pellets. 
13.8. The pellet was air dried, and dissolved in 150 µL H2O and divided into two 
tubes (75 µL each), the concentration was measured at OD260nm using Nanodrop 
spectrophotometer and stored at -20 ⁰C. 
 
3.2.6  Preparation of Electrocompetent E. coli TG1 Cells 
Since the main objective is to obtain as large and diverse VHHs library as possible, 
electroporation was performed to make the cells more receptive for vector. All the procedures of 
preparing the electrocompetent cells were carried out in the cold room at 4 ⁰C. 
Procedure 
1. Buffers (i.e. 1 mM Hepes, pH 7.0) and 10% glycerol were freshly prepared, 
autoclaved and kept at 4 ⁰C. 
2. A single colony of fresh cells of E. coli TG1 was used to inoculate 5 mL 2xTY 
medium in 50 mL Falcon tube, then incubated overnight at 250 rpm and 37 ⁰C. 
3. About 2 mL of the overnight E. coli culture used to inoculate 300 mL 2xTY medium 
in a baffled flask. Then shacked for about 3-4 h at 250 rpm at 37 ⁰C until the OD600nm 
was between 0.8-1.0. 
4. Once the desired OD600nm value was reached, the flask was put on ice for 1 h inside 
the cold room. 
5. The TG1 culture was divided over 6 ice-cooled Falcon tubes, and then centrifuged at 
2,200 g for 7 min at 4 ⁰C. 
6. The supernatant was carefully decanted and gently resuspended the cells in a volume 
of ice-cooled 1 mM Hepes buffer (pH 7.0) equivalent to the original culture-volume. 
Caution: All the resuspension steps must be carried out very gently (e.g. pipetting up and 
down very slowly or swirling). 
7. The suspension was centrifuged at 2,200 g for 6 min at 4 ⁰C. 
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8. The supernatant was carefully decanted and gently resuspended the cells in a volume 
of ice-cooled 10% glycerol equivalent to the half of the original culture-volume. Then 
centrifuged at 2,200 g for 6 min at 4 ⁰C. 
9. The supernatant was carefully decanted and gently resuspended the cells in 10 mL of 
ice-cooled 10% glycerol and all the tubes were pooled together. Then centrifuged at 
2,200 g for 5 min at 4 ⁰C. 
10. Finally, the supernatant was carefully decanted and gently resuspended the cells in 
ice-cooled 10% glycerol to a final volume of 1 mL.  
Critical Step: It is highly preferred to use the TG1 cells immediately for transformation. 
Since storage may significantly reduce their transformation efficiency. 
 
3.2.7  Construction of VHHs Library in Phage Display Vector 
The recently prepared E. coli TG1 electrocompetent cells were immediately transformed with the 
previously ligation mixture stored at -20 ⁰C, and then plated on selective medium in order to 
generate a minimum VHHs library size of about 107 transformants. 
Procedure 
1. The electroporation apparatus was set at 1.8 kV and about 20 electroporation cuvettes 
were kept on ice. 
2. About 50 µL of the electrocompetent cells was placed in the first electroporation 
cuvette as a control, and then applied the electric shock. The vulnerable cells were 
immediately treated with 400 µL SOC medium to recover. 
3. The cuvette was rinsed few times by slow in and out pipetting, another 400 µL SOC 
added to rinse the cuvette once more. 
4. About 75 µL ligation mixture was added to the rest of the competent cells, mixed by 
swirling and kept on ice for 1 min. 
5. The total volume was used as follows: 
 Mixture (competent cells + ligation product)     65 µL 
 First rinse (SOC medium)     400 µL 
 Second rinse (SOC medium)     400 µL 
 All the used volume was collected in one 15 mL Falcon tube. 
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6. The negative control and the transformed mixture were incubated at 200 rpm for at 
least 1 h at 37 ⁰C. 
7. After incubation, a serial dilution was made as follows: 
 Dilution – 1: 900 µL SOC + 100 µL transformed cells 
 Dilution – 2: 900 µL SOC + 100 µL dilution – 1 
 Dilution – 3: 900 µL SOC + 100 µL dilution – 2 
 Dilution – 4: 900 µL SOC + 100 µL dilution – 3 
8. About 100 µL of dilution 3 and 4 was placed on a (90 mm) LB/Amp-Glu (i.e. 100 
µg/mL Ampicillin and 2% (w/v) Glucose) small round agar plates, glass beads were 
used to distribute the cells over the agar surface. Finally, plates were inverted and 
incubated at 37 ⁰C for overnight. 
9. The rest of the competent cells suspension was used to plate about 2 mL/plate all the 
6 large square LB/Amp-Glu agar plates (243 x 243 mm). Glass beads were used to 
distribute the cells over the agar surface. Finally, plates were inverted and incubated 
at 37 ⁰C for overnight, these were used to calculate the transformation efficiency. 
10. After incubation, the library size was calculated from the number of colonies on the 
small agar plates as follows: 
 No. of colonies on each plate x 10 x Dilution factor x Volume  of 
transformed cells = CFU/mL 
11. The colonies were scrapped from the large square agar plates using 3 mL LB 
medium/plate with the aid of sterile cell scraper. The scrapped cells were transferred 
to a 50 mL Falcon tube. Furthermore, each plate was rinsed with 2 mL LB medium 
and transferred to the tubes. Finally, the cells were pelleted down via centrifugation at 
2,200 g for 10 min. 
12. The supernatant was carefully decanted and the cells resuspended in LB medium to a 
final volume of about 20 mL. Then 5 mL of 100 % glycerol was added, afterward, 20 
small 1 mL aliquots in eppendorf tubes were prepared, one of the aliquots was diluted 
100 times in 2 x TY medium, then measured the OD600nm to estimate the total number 
of cells within the scraped library (where: OD600nm of 1 corresponds to about 8x108 
bacterial cell/mL). Finally, all the aliquots and the falcon tubes stored at -80 ⁰C. 
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Critical Step: Calculating the library amplification factor (total number of colonies 
scraped divided by the total number if cells in the small aliquots) will help in estimating 
the number of presented copies of each individual transformant in the library.  
13. Colony PCR was carried out to determine the percentage of colonies from the library 
which  harbors the vector with the right insert size, premix volume for 32 tubes was 
prepared as follows: 
 H2O                    676 µL  
 10x PCR buffer             80 µL 
 dNTPs (10 mM each)              8 µL 
 MP57 primer (20 µM)                       16 µL 
 GIII primer (20 µM)                         16 µL 
 FastStart Taq polymerase(5 units/µL)            4 µL 
 Total volume                      800 µL 
14.   In each PCR tube (31 tubes) 24 µL was transferred, and to each tube a single colony 
from the dilution plates (i.e. 103 or 104) was added with the aid of a sterile 
micropipette tips. The last 32nd tube kept as negative control. 
15. PCR runs was executed as per the following design: 
 Lid temperature:  105 ⁰C 
 Pre-cycle:    95 ⁰C for 6 min (to activate the polymerase) 
 Twenty eight cycle as follows: 
• 94 ⁰C  for  45 sec (denaturation) 
• 55 ⁰C for 45 sec (annealing) 
• 72 ⁰C for 45 sec (extension) 
 Post-cycle:      72 ⁰C for 10 min (final extension) 
 End cycle:                          4 ⁰C 
16. About 8 µL of each Westburg tube was applied, for electrophoretic analysis, on a 1% 
(w/v) agarose gel in TBE buffer and EtBr. In addition, 5 µL of DNA smart ladder was 
used in an adjacent lane. 
17. After running the gel at 125 V for 35 min, the DNA bands are visualized under a UV 
trans-illuminator to find out the number of colonies with the right size (i.e. 700 bp) 
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out of the 31 lanes. Whereas, the molecular weight of the vector with no insert is 
about 300 bp. A satisfactory result should be at least 70%.   
  
3.2.8  Screening and Isolation of Nanobodies®: Phage Display and Biopanning 
After infecting the E. coli TG1 cells with M13K07 helper phage we could generate the library of 
phages which display VHHs on their tips. The presence of the amber stop codon (TAG) between 
the VHHs sequences and the M13K07 gene III allowed the generation of a fraction of virions 
which display the VHHs on their outer tips. These virions are used for a series of consecutive 
rounds of biopanning against the two antigens used in the research work (i.e. SmCB and SmES). 
The enriched phages are then used to infect E. coli cells for (a) further virions’ amplification for 
the next biopanning round and (b) obtaining single individual colonies of bacteria which would 
be used for screening antigen-specific VHHs via ELISA. 
Procedure 
1. In the first day, for each antigen, one well of a flat-bottom ELISA plate was coated 
with 100 µL of antigen solution at a concentration 100 µg/mL in 100 mM NaHCO3 
(i.e. 100 µg/well), the plate covered with Parafilm and kept overnight at 4 ⁰C. 
2. About 1 mL aliquot of the prepared library brought to room temperature and a 
volume contains number of cells 10-1000 times more than the number of the library 
size (i.e. the number of independent transformants) was used to inoculate 100 mL 
2xTY/Amp-Glu medium (the glucose will prevent the leaky expression of VHH-M13 
gene III fused protein from Plac promoter), then incubated at 200 rpm at 37 ⁰C for 
about 2.5 h until OD600nm value equal 0.4-0.6 (i.e. the beginning of the exponential 
growth phase), where, OD600nm of 1 corresponds to ≈ 8x108 cells/mL. 
Critical Step: The number of the used cells must be at least 10 times higher than the 
library size to ensure that each independent transformant is represented and will have the chance 
to be tested against the antigens while performing the biopanning. 
3. Then M13K07 helper phage was added at a multiplicity of infection (MOI) of about 
5-20 to infect the TG1 cells, the culture medium was incubated at room temperature 
for 30 min without shaking. 
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Caution: The shaking of the culture after adding the helper phage may dramatically 
reduce the infection susceptibility of E. coli cells due to the break off the F-Pilli which is 
essential for phage infection. 
4. The culture volume was divided over two Falcon tubes 50 mL, and centrifuged for 10 
min at 1,500 g, then the supernatant was carefully decanted in sodium hypochlorite. 
5. The infected TG1 cells pellet was resuspended in 1 mL 2xTY/Amp-Kan medium, and 
then transferred to 150 mL 2xTY/Amp-Kan medium in a baffled shake flask, then 
incubated overnight shacked at 225 rpm and 37 ⁰C. 
6. In the beginning of the next day, a single colony of fresh cultured TG1 cells was used 
to inoculate 10 mL LB medium in Falcon tube 50 mL, then incubated at 37 ⁰C and 
150 rpm for 2-3 h (until it is cloudy turbid) , these cells are used to amplify the eluted 
enriched phages later on. 
7. The overnight 150 mL 2xTY/Amp-Kan culture was centrifuged for 30 min at 2,200 g 
at 4 ⁰C. The supernatant containing the phage particles was carefully transferred 
(without disturbing the TG1 pellets) equally to 4 Falcon tubes 50 mL, then 1/5th 
volume of PEG/NaCl solution was added to each falcon tube, mixed well by inverting 
and placed on ice for at least 30 min. 
8. After incubation on ice, the tubes were centrifuged for 30 min at 4 ⁰C and 2,200 g. 
the supernatant is carefully decanted in sodium hypochlorite, and the tubes were air-
dried via inverting on a tissue paper under laminar flow hood. 
9. The phage pellets were gently resuspended in PBS (ensure homogenous phage 
suspension and avoid foaming) to a final volume of 1 mL. Then centrifuged for 2 min 
at 15,000 g in order to precipitate any existing bacterial cells, cell rubble and phage 
aggregates. The concentration was measure at OD260nm after 50 to 100 fold dilutions 
was done, followed by adjusting the final concentration to working concentration of 
about 2 x 1012/mL in PBS, where, OD600nm of 1 corresponds to ≈ 3x1010 particles/mL. 
10. The overnight-coated ELISA plate is rinsed well 5x with PBST, then 200 µL of 
blocking milk 2% in PBS was added to the positive well and the non-adjacent 
negative control well as well in order to block the binding sites of the residual protein. 
Afterward, incubated at room temperature for 2 h. After incubation the ELISA wells 
were rinsed at least 5 x with 200 µL PBST. 
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11. An equal volume of phage particles (2 x 1011 particles/mL) and 2% blocking fresh 
skimmed milk were mixed together (i.e. 100 µL each), then added 100 µL of the 
mixture to both the positive and control wells. The plate was incubated at room 
temperature for at least 1 h. 
Critical Step: It is preferred to dilute the phage particles in the same blocking buffer to 
minimize the background and non specific binding between VHH and the buffer 
components. 
12. After incubation, the phage solution was carefully decanted in sodium hypochlorite 
and subsequently rinsed 10x with PBST. 
13. The bound phages were eluted from the wells by adding 100 µL of freshly prepared 
100 mM TEA solution (pH 11.5), and incubated same at room temperature for 10 
min. The eluted phages are neutralized via transferring them to an equal volume (100 
µL) of 1 M Tris-HCl buffer (pH 7.4). 
Pause Point: The neutralized solution can be stored at -80 ⁰C for further procedures. 
Also, 10 µL of the positive well is stored at -80 ⁰C as a backup.  
14. A serial dilution, 10-folds, was prepared by mixing 10 µL of eluted virions with 90 
µL of PBS buffer (the dilution range from 10-1 to 10-7) in a round-bottom ELISA 
plate. 
15. In a new round bottom microtiter plate, 10 µL of each phage dilution was mixed 
separately with 90 µL of exponentially growing E. coli TG1 cells (from Method 
3.2.8. 6), then incubated without shaking for 30 min at 37 ⁰C. 
16. Using a multichannel pipette 10 µL of each dilution was streaked on a small square 
agar plate LB/Amp-Glu. The plate is divided into two sides (i.e. positive sample and 
negative control), then the plates were air-dried under laminar flow hood for a few 
minutes, finally, the plates are inverted and incubated overnight at 37 ⁰C. 
17. The next day, the estimation of the enrichments was carried out by observing the 
number of the grown colonies on the square plates, the bacterial growth at each side 
was compared to the relative dilution of the negative control side. 
18. In parallel, 50 µL of the remaining 90 µL of E. coli TG1 cells of dilution 10-3-10-5 
from the positive coated wells was added to small round agar plates LB/Amp-Glu, 
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then incubated overnight at 37 ⁰C. The next day all the plates are stored at 4 ⁰C for 
further procedures. 
19. The remaining ≈ 180  µL of the neutralized eluted phages (i.e. from positive and 
control) was added to about 2 mL of the exponentially growing E. coli TG1 cells 
(from Method 3.2.8. 6) and gently mixed, then incubated at 37 ⁰C for 30 min without 
shaking, after incubation, additional 8 mL of 2xTY/Amp-Glu medium was added and 
the mixture incubated at 37 ⁰C with shaking at 200 rpm for 45 min. 
20. The incubated infected cells were super-infected with about 107-109 M13K07 fresh 
phage particles, gently mixed, then incubated without shaking at room temperature 
for 30 min. After incubation, the cells were pelletized via centrifugation at 800 g for 
10 min. 
21. The supernatant was carefully decanted in sodium hypochlorite, and the pellet was 
resuspended in 1 mL 2xTY/Amp-Kan medium then transferred to 150 mL of the 
same medium in a baffled flask. Finally, the medium was incubated overnight with 
shaking at 225 rpm and 37 ⁰C. 
22. By the end of the day, another flat-bottom microtiter plate was prepared as explain 
above (from Method 3.8.2. 1) for the consecutive biopanning rounds onward. 
Critical Step: All the available data obtained from different studies indicate the degree of 
difference of the selection of  VHH sequences’ variants in the screening process of 
biopanning procedure, in which one kind of Nanobodies® can be successfully selected 
after the first biopanning round, though, it can be lost during the subsequent rounds. In 
contrast, other clones can be successfully picked only after the third or the fourth round. 
It is crucial to setup the appropriate design of the selection and screening procedures with 
the intention of improving the possibility to come across proper VHHs with particular 
properties. 
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3.2.9 Identification of Phages with Antigen-Specific VHHs Binders: Enrichment Phage 
ELISA and Periplasmic Extract ELISA (PE–ELISA) 
If the selective enrichment was not noticed while performing the consecutive biopanning rounds, 
enrichment phage ELISA offers an alternative method which is more precise. Nevertheless, if the 
enrichment was still insignificantly observed, then, random single colonies from the E. coli TG1 
cells infected with antigen-eluted phages are grown and their periplasmic extracts are screened 
against the antigen of interest through conventional ELISA procedures. The ELISA-positive 
colonies are further screened for their redundancy by colony PCR, Hinf-digestion on single 
colony and DNA sequencing. 
Procedure 
1. Flat-bottom microtiter plate wells were coated with 100 µL of both antigens (i.e. 
SmCB and SmSE) at concentration of 1 µg antigen/mL in 100 mM NaHCO3 coating 
buffer in correspondence to the phage library and all the performed biopanning 
rounds, the plate was covered with Parafilm and incubated overnight at 4 ⁰C. 
2. After incubation, the antigen solutions were removed and rinsed 5x with PBST, 
afterward, 200 µL of 2% fresh skimmed milk in PBS was added to all wells (antigen 
coated and negative control), the plate was incubated at room temperature for 2 h. 
3. The blocking buffer was removed and the wells rinsed 5x with PBST. 
4. A mixture of 100 µL 2% fresh skimmed milk in PBS and equal volume of phage 
library and amplified phages from each panning round at concentration 2 x 1010 
virions was prepared, then 100 µL of the mixture used to coat all the wells. Finally, 
the plate was incubated in room temperature for 1 h. 
5. The coating solutions were removed and the wells rinsed 10x with PBST, then added 
100 µL of 1/2000 dilution of anti-M13-HRP monoclonal antibody conjugate. Then, 
the plate kept in room temperature for 1 h. 
6. The antibody solutions were removed and the wells rinsed 5x with PBST, then added 
100 µL of HRP substrate solution. The plate was kept in dark and the absorbance was 
read at 405 nm after 10 min to 30 min with 5 min time step using a microtiter plate 
reader. 
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Pause Point: If no enrichment was not observed (i.e. at least 2 folds signal strength 
difference between the consecutive panning rounds onwards), the random selection of 
single colonies still a valid approach to be examined. 
7. At least 48 single colonies from the panning round which previously showed a 
relative enrichment for antigen-specific phages were picked and inoculated a 24-well 
flat-bottom tissue culture plates, each well was previously filled with 1 mL TB 
medium containing 100 µg/mL of ampicillin. Concurrently, each picked colony was 
used to streak a reference master agar plat LB/Amp-Glu. These plates incubated 
overnight at 37 ⁰C, and afterward, kept at 4 ⁰C for further procedures. 
Critical Step:  Each streak must be accurately numbered according to the corresponding 
well of the 24-well flat-bottom tissue culture plates  
8. The inoculated 24-well plates were incubated with shaking at 250 rpm, 37 ⁰C for 5-6 
h (the growth progress can be observed visually), then added 10 µL of 100 mM IPTG 
for a final concentration 1 mM. Then, incubated overnight with shaking at 250 rpm 
and 37 ⁰C. 
9. In parallel, a flat-bottom 96-well ELISA plate was coated with 100 µL antigens in 
100 mM NaHCO3 at a final concentration of 1 µg antigen/well. The plate was 
covered with Parafilm and kept overnight at 4 ⁰C. 
10. The next day, the antigen solutions removed and the wells rinsed 5x with PBST, then, 
the wells coated with 200 µL of 2% fresh skimmed milk in PBS. 
11. In a swing-out rotor centrifuge the induced 24-well plates were centrifuged for 15 
min at 4 ⁰C and 2,200 g. The supernatant was carefully decanted without disturbing 
the bacterial cells, and then resuspended the pellets in 200 µL TES buffer. The plates 
kept at 4 ⁰C for 30 min with shaking at 150 rpm. 
12. After incubation, 300 µL of 1/4th dilution TES was added to each well, to causing an 
osmotic shock and extract the Nanobodies® from the periplasm. The plates incubated 
with shaking at 150 rpm and 4 ⁰C for 30 min. Finally, the cells pelletized via 
centrifugation for 15 min at 4 ⁰C and 2,200 g. 
13. During the centrifugation, the blocking buffer in the 96-well ELISA plates was 
removed and the rinsed the wells 5x with PBST. 
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14. The supernatant (i.e. periplasmic extract) from the centrifuged 24-well plates (100 
µL) was transferred to the corresponding positive and negative wells on the 96-well 
ELISA plates. The plates were incubated at room temperature for 1 h. 
15. After incubation, the wells rinsed 5x with PBST, then added 100 µL of 1/1000 
dilution of mouse anti-His tag antibody in PBS, incubated at room temperature for 1 
h.  
16. The antibody solution removed and the wells rinsed 5x with PBST, then added 100 
µL of 1/2000 dilution of anti-mouse alkaline phosphatase conjugate, incubated at 
room temperature for 1 h. 
17. Finally, the enzyme solutions removed and the wells rinsed 5x with PBST, then 
added 100 µL of freshly prepared alkaline phosphatase enzyme substrate, the plates 
kept in dark for 10 min and read the absorbance at 405 nm to 20 min with 5 min step. 
18. For the same periplasmic extract, the colony was considered positive only if the 
absorbance in the antigen-coated well was at least twofold that of the non-coated 
negative control well. 
19. Each positive clone was digested by Hinf restriction enzyme in order to make groups 
of binders with probable identical sequences. 
20. Colony PCR was done, a premix volume for each sample of positive clone was 
prepared as follows: 
 H2O                       84 µL  
 10x PCR buffer            10 µL 
 dNTPs (10 mM each)             1 µL 
 MP57 primer (20 µM)             2 µL 
 GIII primer (20 µM)                          2 µL 
 FastStart Taq polymerase(5 units/µL)        0.3 µL 
 Total volume           ≈ 99 µL 
21. On the tip of sterilized yellow-tip a part of each positive single colony from the 
reference master agar plate was used to streak a numbered agar plate LB/Amp-Glu 
and then placed inside a PCR eppendorf tube containing 96 µL of the above premix 
solution, the tips kept for 15 min while the tubes were placed on ice. 
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22. PCR runs was executed as per the following design: 
 Lid temperature:  105 ⁰C 
 Pre-cycle:    95 ⁰C for 6 min (to activate the polymerase) 
 Thirty two cycle as follows: 
• 94 ⁰C  for  45 sec (denaturation) 
• 55 ⁰C for 45 sec (annealing) 
• 72 ⁰C for 45 sec (extension) 
 Post-cycle:      72 ⁰C for 10 min (final extension) 
 End cycle:                           4 ⁰C 
23. After PCR reaction, 10 µL from each sample were applied on a 1% agarose gel in 
TBE and EtBr and run at 125 V for 30 min, and then the gel was visualized under a 
UV trans-illuminator.  
24. Hinf analysis was carried out to make a sub-selection from the positive clones, for 
each sample a digestion mixture was prepared as follows: 
 Hinf (10 u/µL)                      0.5 µL  
 10x Buffer R            1.1 µL 
 Total volume              1.6 µL 
25. After filling the Westburg tubes with 1.6 µL of the premix, 10 µL of the colony PCR 
reaction was added by means of a multichannel pipette, and then incubated at 37 ⁰C 
for 1 h. 
26. After incubation, 10 µL from each sample were applied on a 2% agarose gel in TBE 
and EtBr and run at 110 V for 30 min, and then the gel was visualized under a UV 
trans-illuminator. 
27. According to the results obtained from Hinf analysis, each selected sample was 
cleaned up for DNA sequencing using MP57 primer, as follows: 
 Colony PCR product                        10 µL  
 ExoSAP-IT            2.6 µL 
 The mixture was incubated at 37 ⁰C for 15 min followed by another 15 min 
at 80 ⁰C. Finally, the mixture stored at -20 ⁰C for sequencing.  
61 
 
28. In addition, a corresponding colony of each positive clone was picked and incubated 
overnight with shaking at 200 rpm at 37 ⁰C in LB medium with ampicillin (at final 
concentration 100 µg/mL). 
29. The next day, the recombinant pMECS phagemid (i.e. the plasmid) was purified 
using GenElute Plasmid Miniprep kit as per the manufacturer protocol. 
30. For each successfully identified VHHs sequence, their purified plasmids were used to 
transform WK6 cells, for the expression of Nanobodies®, as previously described (see 
Method 3.2.7. 1 to 3.2.7. 6).  
Pause Point: A glycerol stock of the transformed WK6 cells must be made for the 
prolonged storage of the VHHs of interest (Sambrook et al., 1989). 
 
3.2.10  Expression and Purification of Antigen-Specific Binders 
After transformation of the recombinant pMECS vector with the VHHs genes of interest into E. 
coli WK6 cells, which lack suppressor (su-). Nanobodies® fused to HA-tag and His6-tag are 
expressed and directed to the periplasm of the cells. The induced WK6 cells are exposed to an 
osmotic shock to extract the periplasm. These extracts are purified via immobilized metal affinity 
chromatography IMAC, the latter is very sufficient to do basic tests such as ELISA and Western 
blot. Furthermore, they can be subsequently purified through size exclusion chromatography. 
Procedure 
1. A single colony of E. coli WK6 containing the plasmid of the VHH of interest was 
used to inoculate a starter culture of 15 mL LB/Amp medium in 50-mL Falcon tube. 
The culture was incubated overnight at 37 ⁰C while shaking at 200 rpm.  
2. The next day, 1 mL of the starter culture was used to inoculate 330 mL TB/Amp-Glu-
Mg medium in a 1 L baffled shake flask and then the culture was incubated for 2-4 h, 
with shaking at 200 rpm at 37 ⁰C until the OD600nm value reached 0.6-0.9. 
3. Each 330 mL TB/Amp-Glu-Mg medium was induced with 330 µL 1M IPTG for a 
final concentration 1 mM. Afterward, the culture was incubated overnight with 
shaking at 200 rpm at 28 ⁰C until the OD600nm of the undiluted culture reached 20-30. 
Finally, the culture was transferred to appropriate tubes for centrifugation at 11,300 g 
for 8 min at 4 ⁰C. 
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4. The supernatant of each 330 mL culture was decanted and the cell pellet was fully 
suspended in 4 mL TES buffer through reciprocating pipetting. Subsequently, the 
suspension was kept on ice in the cold room, at 4 ⁰C, on a shaker at 200 rpm for 6 h. 
5. While cells still on ice 8 mL of 1/4th dilution TES buffer was added, and kept in the 
cold room on ice and shaking at 200 rpm overnight. 
6. The next day, all the tubes were centrifuged for 30 min at 11,300 g at 4 ⁰C and then 
the supernatant containing the periplasmic extract was carefully transferred to 50-mL 
Falcon tubes. 
7. The PD-10 columns were prepared for IMAC purification of the His6-taged VHHs, 
for each liter of E. coli culture 1 mL of the HIS-Select gel was used with binding 
capacity of about 15 mg His-tag VHH/mL. 
8. In the beginning, the HIS-Select gel was equilibrated with 50 mL PBS, then 40 mL of 
the supernatant was discarded and the rest volume was equally distributed over the 50 
mL Falcon tubes with the periplasmic extract. The mixture was incubated at 4 ⁰C for 
30 min with gentle shaking. 
9. After incubation, the mixture was poured into the PD-10 column with filter fitted 
inside and was left to drain by gravity. 
10. The His-Select gel washed with 20 column volumes with PBS until the last droplet 
OD280nm value was close to zero. 
11. The Ni-ion bound Nanobodies® was eluted by adding 5 columns volume of 500 mM 
Imidazole in PBS, the elution continued until the last droplet OD280nm value was less 
than 0.15. 
12. Finally, the Ni-NTA fractions were ran on 12% sodium-dodecyl-sulfate poly-
acrylamide-electrophoresis gel (SDS-PAGE) to confirm Nanobodies® elution in the 
samples. The fractions were pooled and their approximate protein concentration was 
measured at OD280nm at their individual extinction coefficients’ values using 
Nanodrop® spectrophotometer. 
13. The Imidazole was replaced with PBS buffer by using Vivaspin column with 
molecular weight cut off value MWCO of 5 kDa. 
Caution:  Nanobodies® eluted with Imidazole only stored at 4 C, freezing may cause 
irreversible precipitation. 
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4 Results and Discussion 
4.1 Camel Immunization 
In order to generate antigen specific HCAbs, a three years old camel of about 250 Kg weight, 
was immunized with SmCB and SmES antigens. Medical follow up was performed on regular 
basis. Evidently, no significant health problem occurred during the entire immunization period 
until the blood withdrawing date (i.e. 8 weeks). 
 
4.2 Library Construction 
Lymphocytes of the immunized camel were extracted from 100 mL of peripheral blood PBL 
using Leucosep™ tube. A total amount of about 40 µg mRNA was extracted from the PBL and 
was subsequently used as a template for generating the first complementary strand of 
complementary DNA. Afterward, the 1st cDNA was as a template to amplify the gene fragments 
encoding for the variable domain of the heavy chain only antibodies and the conventional 
antibodies up to the CH2 domain. The resultant fragments bands are corresponding to VH-CH1-
hinge-CH2 and VHH-hinge-CH2 regions of corresponding sizes of about ≈ 900 bp and ≈ 700 bp  
respectively. Figure 1.14 illustrates the 1st PCR products and the resulting bands after separation 
on 1% agarose gel electrophoresis. 
 
Figure 1.14. 1st PCR products gel electrophoresis on 1% agarose gel. Both A & B represent the 
amplification products of the 1st strand cDNA PCR containing fragments with two different sizes. 
The red arrow points at the 900 bp fragment corresponds to VH-CH1-hinge-CH2, whereas, the 
blue arrow points at the 700 bp fragment corresponds to VHH-hinge-CH2. 
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The 700 bp fragment band purified from the 1% agarose gel using the QIAquick Gel 
Extraction Kit (Qiagen), then the purified products used as a template for a nested PCR 
amplification processes specific to VHH-only sequences producing a corresponding DNA 
fragment of about 400 bp.  Figure 1.15A illustrates the purified 700 bp band after purification, 
while, Figure 1.15B represents the product of the 2nd nested PCR. 
 
Figure 1.15. Purified and Nested PCR Products Gel Electrophoresis on 1% Agarose Gel. A. 
the blue arrow points at the purified 700 bp fragment correspond to the VHH-CH2 region. B. the 
blue arrow points at the product of the 2nd nested PCR of about 400 bp and correspond to the 
VHH only fragment. 
The PCR fragments and the pMECS vector were digested with the same restriction 
enzymes via two consecutive digestion sessions. Figure 1.16 illustrates the digested purified 2nd 
PCR product and the vector at two different volumes; 0.5 and 1 µL per lane (1 & 2) and (3 & 4) 
respectively. 
 
Figure 1.16. Digested VHH Fragment and Vector Gel Electrophoresis on 1% Agarose Gel. 
The red arrow points at the digested pMECS vector, while, the blue arrow points at the VHH 
fragment. 
Vector 
VHH 
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The pMECS clean ligation was subsequently transformed into the freshly prepared 
electrocompetent cells of Escherichia coli TG1 strain by electroporation. Finally, a library size 
of about 1.2 x107 transformants (i.e. clones) was obtained. Figure 1.17 illustrates the products of 
the colony PCR, from 30 randomly selected single colonies from the dilution plates, which 
determined about 80 % (i.e. 24 clones with correct insert size out of 30 picked samples) of the 
clones in the constructed library contained a correct insert size of about ≈ 700 bp encodes for the 
bacteriophage gIIIp protein (≈ 300 bp) fused to the VHH (≈ 400 bp).  
 
Figure 1.17. Colony PCR for Library with Correct Insert-Size Estimation. The blue arrows 
point at the correct size, the lanes numbers between brackets signify those with incorrect sizes. 
 
4.3 Screening and Isolation of Nanobodies®: Phage Display and Biopanning 
After infecting the E. coli TG1 cells with M13K07 helper phage, a phage library which displays 
VHHs on their tips was generated. These virions used for four consecutive rounds of biopanning 
against the two antigens (i.e. SmCB and SmES). There was no significant enrichment in phages. 
Nonetheless, random 47 single individual colonies of bacteria for each antigen were used for 
screening antigen-specific VHHs via Periplasmic Extract ELISA (PE-ELISA). Only two 
colonies corresponding to SmES gave (≥ 2) the reading absorbance value and were considered 
positive, whereas, thirty six colonies corresponding to SmCB were considered positive, divided 
into groups with regard to their absorbance intensities. Furthermore, the redundancy of the 
ELISA-positive colonies was further screened for their redundancy by colony PCR, Hinf-
digestion on single colonies and DNA sequencing. 
Table 1.11. PE ELISA Readings for SmCB Antigen-Specific VHH binders - Plate A & B 
SmCB 1 2 3 4 5 6 7 8 9 10 11 12 Plate-A 
A 0,085 0,07 0,074 0,086 2,889 0,36 0,126 1,458 0,108 0,1 0,097 3,031 
B 0,065 0,067 0,077 0,082 2,821 0,118 0,084 1,406 0,088 0,089 0,088 2,812 
C 0,082 0,103 0,154 3,041 0,15 0,18 3,032 2,46 0,091 0,257 0,123 0,13 
D 0,063 0,072 0,075 2,764 0,077 0,077 2,918 2,281 0,08 0,078 0,077 0,079 
E 0,285 0,081 0,091 0,345 2,771 2,732 0,38 0,319 0,177 0,217 2,802 0,347 
F 0,096 0,072 0,081 0,088 3,053 2,359 0,106 0,107 0,083 0,085 2,608 0,118 
G 2,763 0,082 0,074 0,099 0,139 0,112 0,074 2,359 0,079 0,139 0,167 0,203 
H 2,748 0,079 0,071 0,074 0,082 0,087 0,083 1,821 0,082 0,082 0,075 0,078 
             SmCB 1 2 3 4 5 6 7 8 9 10 11 12 Plate-B 
A 0,201 0,346 0,263 0,221 0,196 0,183 0,128 3,158 0,164 0,11 0,262 0,193 
B 0,111 0,152 0,115 0,124 0,12 0,157 0,131 2,69 0,147 0,192 0,143 0,122 
C 0,112 0,438 0,344 0,837 0,29 0,345 0,334 0,3 0,354 0,224 1,053 0,194 
D 0,103 0,219 0,248 0,653 0,234 0,147 0,178 0,149 0,227 0,104 0,709 0,083 
E 0,107 0,146 0,302 0,38 0,316 0,445 2,824 0,244 0,259 0,453 0,118 0,163 
F 0,081 0,082 0,095 0,125 0,094 0,117 2,321 0,081 0,079 0,245 0,079 0,081 
G 3,524 0,095 0,102 0,5 2,229 0,349 0,288 0,098 0,122 0,107 0,303 2,841 
H 3,398 0,085 0,083 0,227 1,687 0,082 0,083 0,081 0,078 0,08 0,102 2,563 
 
Where: 
  Group 1    Group 3 
  Group 2   Group 4 
  Negative Control  
 
66
Table 1.12. PE ELISA Readings for SmES Antigen-Specific VHH binders - Plate A & B 
SmES 1 2 3 4 5 6 7 8 9 10 11 12 Plate-A 
A 1,289 3,069 3,425 3,206 3,004 3,006 0,881 2,868 2,835 0,688 2,823 0,084 
B 0,773 3,172 3,397 3,242 2,947 2,708 1,066 3,122 2,888 0,856 2,508 0,087 
C 3,459 3,373 0,358 3,398 3,259 2,797 3,178 3,025 2,741 0,945 0,094 3,586 
D 3,477 3,373 0,232 3,122 3,346 2,924 2,751 3,022 2,639 0,657 0,087 2,555 
E 3,543 3,54 3,268 3,29 0,462 3,089 2,824 2,8 2,912 2,974 2,626 2,745 
F 3,312 3,31 3,422 2,93 0,151 3,185 2,919 3,178 2,743 2,729 2,481 2,707 
G 3,65 3,479 0,104 3,12 3,242 3,389 3,315 3,212 2,531 2,966 2,854 2,89 
H 3,41 3,201 0,086 2,986 3,346 2,94 2,676 2,871 2,629 2,571 2,551 2,649 
             SmES 1 2 3 4 5 6 7 8 9 10 11 12 Plate-B 
A 3,349 3,218 2,935 3,282 3,318 1,901 3,249 3,364 3,116 2,628 0,258 2,818 
B 3,224 3,423 3,144 2,886 3,32 2,199 3,463 3,59 3,509 3,062 0,283 3,963 
C 3,106 3,427 0,374 3,13 3,773 3,515 3,464 1,809 2,538 2,875 1,049 2,839 
D 3,382 3,16 0,293 3,052 3,312 3,408 3,277 1,629 3,15 3,108 1,035 2,754 
E 3,23 3,224 1,824 2,997 0,375 1,94 3,693 3,46 3,937 3,02 2,469 3,19 
F 3,078 3,129 1,752 3,009 0,097 2,012 3,184 2,869 3,139 3,08 2,662 2,786 
G 3,26 3,341 3,28 3,193 1,343 3,124 3,451 3,904 3,227 2,972 3,38 2,2 
H 3,115 3,228 3,193 3,068 1,046 2,946 3,011 2,787 2,932 3,016 3,158 1,546 
 
Where: 
  Group 1   
  Negative Control 
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Figure 1.18 illustrates the colony PCR products of three sample clones for SmES antigen (i.e. 
two positive binders and one random), and all the positive selected binders of SmCB. Five clones 
seemed to be contaminated and didn’t offer any good candidate, whilst, thirty seven clones were 
found with the correct insert size and were put forward for further Hinf-digestion analysis. 
 
  Figure 1.18. Colony PCR for Selected Binders from PE ELISA. From E1 to E3 are colonies 
for the SmES two positive binders and one negative sample which was randomly selected. From 
C1 to C39 are colonies for the SmCB positive binders. 
All the positive colonies were subjected for further Hinf-digestion in order to assort the positive 
clones into groups. Figure 1.19 illustrates the results after digestion. 
 
Figure 1.19. The Products of Hinf-Digestion. There are eight different groups of positive 
clones. 
A A D C B F G C H E A C B G 
All the positive clones were sent for sequencing and then all sequences were translated into their corresponding amino acids using Clone 
Manager-6 program. The produced amino acids sequences were aligned and divided into groups, using ClustalW2 multiple sequence 
alignment program. Noteworthy, some of the binders’ retrieved sequences were omitted, and are not shown here in the study, due to 
inadequacy and erratic manner of their results; mostly it occurs while sequencing, and clones should go for another attempt: 
 
   <------------------FR1-----------------> <---CDR1--->  <------------FR2----------->   <---CDR2--->   
NbSmCB6     QVQLQESGGGSVQAGGSLRLSCTVSG   ETYRSRY        LAWFRAAPGKEREGVAVI     LPGGGTTY   
<--------------------------FR3--------------------------->  <------------CDR3------------> <------FR4------> 
                           YTDSVKGRFTISQDIPKTTVYLQMNSLKPEDTAMYYC    AASTSMYLYDRKFSADAYNY   WGQGTQVTVSS 
 
<------------------FR1-----------------> <-CDR1->    <-------------FR2------------>  <---CDR2--->   
NbSmCB2    QVQLQESGGGSVQAGGSLKLSCTASG  YIYKTF WGWFRQAPGKEREGVALF  ATDGIYID   
NbSmCB3    QVQLQESGGGSVQAGGSLKLSCTASG   YIYKTF WGWFRQAPGKEREGVALF  ATDGIYID   
NbSmCB25         QVQLQESGGGSVQAGGSLKLSCTASG  YIYKTF WGWFRQAPGKEREGVALF  ATDGIYID   
<--------------------------FR3--------------------------->  <------------CDR3-----------> <------FR4------> 
NbSmCB2    YADSVKGRFTISTDNVKNTVYLMMTNLKPEDTAIYYC   AAGFGGDYSRRWQIGSWIY  WGRGTQVTVSS 
NbSmCB3   YADSVKGRFTISTDNVKNTVYLMMTNLKPEDTAIYYC   AAGFGGDYSRRWQIGSWIY  WGRGTQVTVSS 
NbSmCB25  YADSVRGRFTISTDNVKNTVYLMMTNLKPEDTAIYYC   AAGFGGDYSRRWQIGSWIY  WGRGTQVTVSS 
 
<------------------FR1-----------------> <-CDR1->  <------------FR2------------>   <---CDR2--->   
NbSmCB11        QVQLQESGGGSVQAGGSLRLSCKASS    YTGI        MAWFRQSLGKEREGVAAI      RTGTHETY   
NbSmCB13       QVQLQESGGGSVQAGGSLRLSCKASS    YTGI        MAWFRQSLGKEREGVAAI      RTGTHETY 
NbSmCB14        QVQLQESGGGSVQAGGSLRLSCKASS    YTGI        MAWFRQSLGKEREGVAAI      RTGTHETY   
NbSmCB15        QVQLQESGGGSVQAGGSLRLSCKASS    YTGI        MAWFRQSLGKEREGVAAI      RTGTHETY   
NbSmCB27        QVQLQESGGGSVQAGGSLRLSCKASS    YIGI         MAWFRQSPGKEREGVAAI      RTGTHGTY   
<--------------------------FR3---------------------------->  <-----------CDR3-----------> <------FR4-------> 
NbSmCB11  YHDSVKGRFTISRDNAEKTVYLQMNSLKPEDTAMYYC    AAARLSVYEWYSDSRYNF   WGQGTQVTVSS 
NbSmCB13  YHDSVKGRFTISRDNAEKTVYLQMNSLKPEDTAMYYC    AAARLSVYEWYSDSRYNF   WGQGTQVTVSS 
NbSmCB14   YHDSVKGRFTISRDNAEKTVYLQMNSLKPEDTAMYYC    AAARLSVYEWYSDSRYNF   WGQGTQVTVSS 
NbSmCB15  YHDSVKGRFTISRDNAEKTVYLQMNSLKPEDTAMYYC    AAARLSVYEWYSDSRYNF   WGPGTQVTVSS 
NbSmCB27  YDDSVKGRFTISRDNAENTVYLQMNSLKPEDTAMYYC    AAARLSVYEWYSDSRYNF   WGQGTQVTVSS 
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<------------------FR1-----------------> <-CDR1->  <-------------FR2------------->   <---CDR2--->   
NbSmCB10        QVQLQESGGGSVQAGGSLRLSCVAST  YTYTS MGWFRQAPGKEREGVASI NSRFNTNTY  
NbSmCB17         QVQLQESG??SVQAGGSLRLS?VAST  YTYTS MGWFRQAPGKEREGVASI NSRFNTNTY  
NbSmCB18        QVQLQESGGGSVQAGGSLRLSCVAST  YTYTS MGWFRQAPGKEREGVASI NSRFNTNTY  
NbSmCB19     QVQLQESGGGSVQAGGSLRLSCVAST  YTYTS MGWFRQAPGKEREGVASI NSRFNTNTY  
NbSmCB20        QVQLQESG?GSVQAGGSLRLS?VAST  YTYTS MGWFRQAPGKEREGVASI NSRFNTNTY 
NbSmCB21         QVQLQESGGGSVQAGGSLRLSCVAST  YTYTS MGWFRQAPGKEREGVASI NSRFNTNTY  
NbSmCB22     QVQLQESGGGSVQAGGSLRLSCVAST  YTYTS MGWFRQAPGKEREGVASI NSRFNTNTY  
NbSmCB28         QVQLQESGGGSVQAGGSLRLSCVAST  YTYTS MGWFRQAPGKEREGVASI NSRFNTNTY  
NbSmCB29         QVQLQESGGGSVQAGGSLRLSCVAST  YTYTS MGWFRQAPGKEREGVASI NSRFNTNTY  
NbSmCB30         QVQLQESGGGSVQAGGSLRLSCVAST  YTYTS MGWFRQAPGKEREGVASI NSRFNTNTY  
 
<--------------------------FR3---------------------------->  <-----------CDR3-----------> <------FR4-------> 
NbSmCB10  YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC    AAGPLQGGVTWDKPSGYTR  WGQGTQVTVSS  
NbSmCB17  YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC    AAGPLQGGVTWDKPSGYTR  WGQGTQVTVSS 
NbSmCB18  YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC    AAGPLQGGVTWDKPSGYTR  WGQGTQVTVSS 
NbSmCB19   YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC    AAGPLQGGVTWDKPSGYTR  WGQGTQVTVSS 
NbSmCB20  YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC    AAGPLQGGVTWDKPSGYTR  WGQGTQVTVSS 
NbSmCB21  YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC    AAGPLQGGVTWDKPSGYTR  WGQGTQVTVSS 
NbSmCB22  YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC    AAGPLQGGVTWDKPSGYTR  WGQGTQVTVSS 
NbSmCB28   YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC    AAGPLQGGVTWDKPSGYTR  WGQGTQVTVSS 
NbSmCB29  YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC    AAGPLQGGVTWDK?SGYTR  WGQGTQVTVSS 
NbSmCB30  YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC    AAGPLQGGVTWDKPSGYTR  WGQGTQVTVSS 
 
<------------------FR1-----------------> <--CDR1--> <------------FR2------------>    <---CDR2--->   
NbSmCB8         QVQLQESGGGSVQDGGSLRLSCVASG  YTYSIKW   RGWFRQAPGKEREAVAAI GTGSGATY   
NbSmCB16        QVQLQESGGGSVQDGGSLRLSCVASG  YTYSIKW    RGWFRQAPGKEREAVAAI GTGSGATY   
<--------------------------FR3---------------------------->  <-----------CDR3----------> <------FR4-------> 
NbSmCB8    YDDSVRGRFTISQDNAQNTVYLQMSSLKPEDTALYYC     AASDSQSFLLTRSDRYKY WGQGTQVTVSS  
NbSmCB16  YDDSVKGRFTISQDNAQNTVYLQMSSLKPEDTALYYC     AASDSQSFLLTRSDRYKY WGQGTQVTVSS 
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<------------------FR1----------------->  <-CDR1->  <------------FR2------------->   <---CDR2--->   
NbSmCB9          QVQLQESG??SVQAGGSLRLSCEASG     YNISTYC    MGWFRQAVGKEREGVANI     GSSGGRTY 
<--------------------------FR3---------------------------->  <-----------CDR3-----------> <------FR4-------> 
NbSmCB9  YADSVKGRFTISRDNAKNVVYLQMNNLKPEDTAIYYC     ATNSLWCPGFQASRWNY  WGQGTQVTVSS 
 
<------------------FR1----------------->  <-CDR1->  <------------FR2------------->   <---CDR2--->   
NbSmCB7          QVQLQESG?GSVQAGGSLRLSCAASG   YTSAPY? MGWL???VPGKECESVSS?       ?TAGFPN    
NbSmCB26         QVQLQESGGGSVRAGGSLRLSCAASG   YTSAPYL MGWL?RQVPGKECESVSSM     STAGFPN    
               <--------------------------FR3---------------------------->  <-----------CDR3----------> <------FR4-------> 
NbSmCB7  YADSV??RFTISRDY?KMTVDLQMNNL?PDDTGMYYC    A?SGRWRC  DGQGTQ?TVSS 
NbSmCB26  YADSVKGRFTISRDYAKMTVDLQMNNLKPDDTGMYYC   AASGRWRC  DGQGTQVTVSS 
 
<------------------FR1----------------->  <-CDR1->  <------------FR2------------>   <---CDR2--->   
NbSmES1           QVQLQESGGGSVQAGGSLRLSCAASG  NSRRPLKY IGWFRQPPGKEREGIAAI HLAGGSTW  
NbSmES2           QVQLQESGGGSVQAGGSLRLSCAASG  NSRRPLKY IGWFRQPPGKEREGIAAI HLAGGSTW   
NbSmES3     QVQLQESGGGSVQAGGSLRLSCAASG  NSRRPLKY IGWFRQPPGKEREGIAAI HLAGGSTW   
NbSmES5     QVQLQESGGGSVQAGGSLRLSCAASG  NSRRPLKY IGWFRQPPGKEREGIAAI  HLAGGSTW 
               <--------------------------FR3---------------------------->  <-------------CDR3------------> <------FR4-------> 
NbSmES1  YSDSVKGRFTISQDRDKNTVYLQMNSLKPEDTAIYYC      AALSKSRVGYWRSSREYKY     WGQGTQVTVSS 
NbSmES2   YSDSVKGRFTISQDRDKNTVYLQMNSLKPEDTAIYYC      AALSKSRVGYWRSSREYKY     WGQGTQVTVSS 
NbSmES3     YSDSVKGRFTISQDNAKNVVYLQMNSLKPEDTAIYYC      AALSKSRVGYWRSSREYKY     WGQGTQVTVSS 
NbSmES5    YSDSVKGRFTISQDRDKNTVYLQMNSLKPEDTAIYYC     AALSKSRVGYWRSSREYKY     WGQGTQVTVSS 
 
<------------------FR1----------------->  <--CDR1-->  <------------FR2------------->   <---CDR2--->   
NbSmES4     QVQLQESGGGSVQAGGSLRLSCAASG    NTDN-IYR      MTWFRQAPGKEREGVASM       QRNGRGIY 
                      <--------------------------FR3---------------------------->  <-------------CDR3------------> <------FR4-------> 
NbSmES4   YANSVKGRFTISQDNAKNTLYLQMNSLKPEDTGVYYC         TT-------GWRALRLLP-        DRRGTQVTVSS 
 
Where: 
FR1,2,3,4: Fram Works 1, 2, 3 and 4 
CDR1,2,3: Complementarity Determining Regions 1, 2 and 3 
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4.4 Expression and Purification of Antigen-Specific Binders 
The recombinant pMECS vector with the VHHs genes of interest were transformed into E. coli 
WK6 cells, which lack suppressor (su-). Nanobodies® fused to HA-tag and His6-tag are 
expressed and directed to the periplasm of the cells. The induced WK6 cells are exposed to an 
osmotic shock to extract the periplasm. These extracts are purified via Ni-NTA immobilized 
metal affinity chromatography IMAC. The eluted Ni-NTA fractions were pooled and ran on 
sodium-dodecyl-sulfate poly acrylamide electrophoresis gel (SDS-PAGE), using 12% SDS 
bistris gel (Invitrogen), to confirm the expression.  
As a final point, the approximate protein concentration was measured at OD280nm at their 
individual extinction coefficients’ values using UV Nanodrop® spectrophotometer. Figure 1.20 
illustrates an SDS-PAGE results for one of the produced binders, a systematic follow-up for the 
presence of the VHH along with the entire processes. 
 
Figure 1.20. VHHs Presence and Purity Confirmation via 12% SDS-PAGE. M. Page Ruler™ 
Prestained Protein Ladder (Fermentas). 1. First flow-through of IMAC, 2. Native PE extract, 3. 
Second flow-through of IMAC, and 4. IMAC purification of PE extract of one of the expressed 
Nanobodies®. All the Nanobodies® were displayed as a single band of approximately 15 kDa 
matching their theoretical molecular weight values. 
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Information about the physical properties of the selected Nanobodies® is necessary for 
further experimental set-ups, they were obtained based on the amino-acid sequences of each 
VHH protein, including the peptide tags, using the ProtParam tool at the ExPASy proteomics 
server of the Swiss Institute of Bioinformatics. 
Table 1.13. Physical properties & final concentrations of SmCB and SmES specific Nanobodies® 
VHH Name 
Number of amino acids 
(including HA & His6 tag) 
Molecular 
weight (Da) 
Theoretical 
pI 
Extinction 
coefficient 
Yield 
(mg/L) 
NbSmCB2 144 16004.7 7.17 2.835 8.47 
NbSmCB9 141 15624.1 7.86 2.457 5.85 
NbSmCB10 144 15734.2 8.56 2.090 8.91 
NbSmCB11 141 15809.3 7.25 2.175 8.98 
NbSmCB16 144 15843.2 6.64 2.170 2.01 
NbSmCB26 133 14387.9 7.16 1.697 12.9 
NbSmES4 137 15194.8 9.39 1.606 0.1 
NbSmES5 146 16226.9 9.39 2.366 1.2 
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5 Conclusion 
 
There are over 200 million people worldwide infected with Schistosomiasis, 120 million 
symptomatic patients and 600 million individuals live at risk, in addition, there are 280,000 of 
new cases every year mostly among the world’s poorest populations where they lack the 
infrastructure and resources necessary to establish proper equipped laboratories for diagnosis and 
treatment. Given the high risk of complications, and for further extent, mortality due to Bilharzia, 
a rapid and accurate schistosoma diagnosis is critical for the appropriate treatment of affected 
individuals. In the study presented here, we wanted to establish a sensitive technique for 
detecting parasite specific antigen utilizing Nanobodies® to be used as molecular imaging 
diagnostic and a therapeutic agent for a novel immunotherapeutic approach. 
Currently, there are more than 20 therapeutic mAb products on the healthcare market and 
more than 100 in clinical trials, it is logical that engineered antibodies have come of age as 
biopharmaceuticals candidates (Reichert, 2008). Despite various beneficial characteristics of the 
conventional antibodies, the low intrinsic toxicity of the Nanobodies® together with their size 
characteristics and their high specificity and affinity for the antigen render them more proficient 
tools for various approaches – e.g. anti-biomarkers, drug delivery, in addition, physo and 
chemotherapeutic agents.  
In this study, we could successfully generate different Nanobodies® against two 
representative schistosoma antigens (i.e. S. mansoni Cathepsin B and Execratory Secretory 
antigens). Consequently, the obtained data suggests that these anti-schistosoma Nanobodies® can 
be properly designed for being used as a premier molecular research tool with the aim of 
unraveling the in vivo molecular mechanism of the host cell invasion. Moreover, wide range of 
novel Bio-Nano-Conjugate systems can be constructed with metallic, polymeric and magnetic 
nanoparticles for creating state-of-the-art healthcare theragnostic tools. For instance, rapid lateral 
flow assays, surface plasmonic resonance, colorimetric tests, magnetic concentrating technique, 
magnetic targeting and magneto hyperthermia applications. 
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CHAPTER 2: CONSTRUCTION OF 99mTC LABELED-sdAb-GRAPHENE-
COATED-NANOMAGNET BIOCONJUGATE – PROOF OF CONCEPT 
1 Magnetism: BioNanosystems for Magnetic enforced-Active-Targeting 
1.1 Nano-Magnetism from Ferro to Superparamagnets: The Prologue 
The etiology of magnetism is an old science that withdrawn an immense attention and interest 
during the past centuries. The phenomenon exists in a material, commonly a metal, when the 
electrons of a typical atom rotate around it’s nucleus in a certain radius – r and angular velocity – 
ω. The atomic number – Z determines the total number of electrons and the charge of each 
electron is given by a value of (e). In general, when a charged particle is in motion around a 
circular path it generates an electric current with a total amplitude value equals (µoIA), where 
(A) is the area enclosed of the circular motion of each electron, it equals (A = πr2), and (I) is the 
generated current’s intensity, it equals (I = -eω/2π). The produced magnetic moment generated 
by the motion of the charged electron around the atomic circular path, which is typically an 
orbital motion, is given by: 
𝑴𝑴 = −𝝁𝝁ₒ𝒆𝒆𝒆𝒆𝒓𝒓𝟐𝟐
𝟐𝟐
 
When the outermost shell(s) of an atom are not completely filled they have permanent net 
magnetic moments. These moments are created from the summation and subtraction of the 
combination of the total spin and orbital motions of its electron(s). Generally, the actual 
magnetism of these numerous number of electrons has insignificant values, because of their 
intrinsic random path orientations inside the magnetic matter. Nevertheless, when exposed to 
external magnetic/electric fields, the magnetic dipole moments generated from the randomly 
moving electrons align themselves in a way that creates a net magnetic field in a certain direction 
matching the one of the externally applied field. A ferromagnetic material has a natural magnetic 
moment, which implies that the components of the electron moments and the orbital motion’s 
moments are arranged parallel to each other. This spontaneous magnetisation is temperature 
dependant (i.e. it vanishes above Curie temperature). As the temperature increases, thermal 
motion, or entropy, competes with the ferromagnetic tendency for dipoles to align, and a 
ferromagnetic material becomes paramagnetic (i.e. the magnet will lose its magnetism) 
(Balakrishnan, 2011). 
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For instance, the Curie temperature of some common materials is: Iron (Fe) 770 ⁰C, Cobalt (Co) 
1130 ⁰C, Nickel (Ni) 358 ⁰C and Iron Oxide (Fe2O3) 622⁰C (Buschow, 2001). 
 
Figure 2.21. Illustration of Ferromagnetic Domains (Harris, 2002) 
 
A typical ferromagnetic material reaches its magnetisation saturation when it is exposed 
to external magnetic field. Figure 2.22 illustrates the classical hysteresis curve obtained 
throughout the magnetizing and demagnetizing process of a bulk unmagnetized ferromagnetic 
material. In the absence of any external magnetic field, the magnetic moments of the same 
orientation are intrinsically organized in regions called magnetic domains which are separated by 
virtual barriers know as “domain walls”. Each of these domains has a permanent net 
magnetisation (M) in a certain direction. Although, the orientation of the domains in the bulk 
material is random it results in an innate net magnetisation value (Figure 2.22a), a more 
energetically favorable configuration. Upon exposure to a sufficiently large external magnetic 
field, the domains with magnetisation direction all along the magnetic field axis enlarge while 
the others get smaller in a phenomenon known as “domain wall displacement” (Gubin et al., 
2005) (Figure 2.22b). The alignment continues until all moments are aligned in the direction 
corresponding to that of the external field (Figure 2.22c) at this configuration the material 
reaches its magnetisation saturation (Ms). When the external field is removed the materials’ 
magnetisation does not relax-back to the initial state. However, some energy is stored 
maintaining a net magnetisation known as “remanent magnetisation ” (Mr). An external magnetic 
field of a definite magnitude must be applied in the opposite direction in order to demagnetize 
the material and reduce its magnetisation back to zero that is known as coercivity field (Hc).  
Continuing to expose the material to the opposite field, the same behavior is observed but in 
opposite manner. Hysteresis refers to the inability of retracing the magnetisation curve, since the 
material retains a memory of its magnetisation (Mr) (Balakrishnan, 2011). 
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Figure 2.22. Hypothetical Domain Configuration and Hysteresis Loop of an Unmagnetized 
Ferromagnetic Material (Taylor, 2010) 
 
In nanoscaled magnetic particles, the above scenario diametrically opposed, at a certain 
nano-size limit particles become so small that they consist of a single domain, leading to the 
emergence of a distinctive phenomenon known as “Superparamagnetism”, in which 
nanoparticles are found superior to ferromagnetic particles due to the absence of remanent 
magnetisation . These particles reveal magnetic properties only in the presence of an external 
magnetic field (Giri, 2003). In the case of single domain magnetic particles the difference 
between the minimum and maximum potential energy per unit volume of the particle’s magnetic 
moment is significantly smaller than its thermal energy. Consequently, the orientations of these 
magnetic moments are in constant change due to the thermal agitation. Therefore, thermal energy 
becomes large enough to cause random fluctuation in the absence of any external fields (Taylor, 
2010). Thus, nanosized particles seem to lack hysteresis loss, nevertheless, their coercivity value 
does not rest at zero, various theoretical calculations indicate that this happens for different 
particles in different size ranges, for instance, 15-30 nm for Fe, 70 nm for Co and 32-55 nm for 
Ni (Gubin et al., 2005).  
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Figure 2.23 illustrates the change in coercivity value as a function of particle diameter. Where: 
(Dcrt) is the particles’ critical diameter and (Dsp) is the superparamagnetic diameter.  
 
Figure 2.23. Coercivity as a Function of Particle Diameter (Ashby et al., 2009) 
 
Figure 2.24 illustrates the magnetisation curve of superparamagnetic particles, in which, there is 
no hysteretic nature of the curve and a very small coercivity field magnitude exists (Taylor, 
2010).  
 
Figure 2.24. Hypothetical Magnetisation Curve of Common Superparamagnetic 
Nanoparticles (Taylor, 2010) 
 
1.2   Carbon Nanostructures: Graphene-Encapsulated Nanomagnets 
The implementation of the extraordinary properties of superparamagnetic nanoparticles is 
hindered by many factors that limit their applications. The chemical stability is one of the most 
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critical factors where they are used in complex fluid systems – e.g. biological fluids. In addition, 
dispersion concerns are also a crucial factor, in view of the fact that, most of the nanoparticles 
will tend to aggregate in order to minimize their surface free energy. Furthermore, nanoparticles 
are easily oxidized in presence of free oxygen, therefore, they might lose partially or entirely 
their significant magnetisation . As a result, numerous attempts have been devoted to furnish 
these nanomagnets with appropriate protection through encapsulation into an inert chemical 
compounds – e.g. consecutive graphene layers (Mahmood et al., 2009).  
Various coating materials were successfully employed, for example, gold, silica, 
transition-metal oxides and carbon-encapsulations. The use of gold cannot be recognized as an 
economic-friendly approach. The covalent bonds on silica and other transition-metal oxides are 
prone to hydrolysis due to the instability of the silica shells under prolonged exposure to basic 
conditions. Finally, a carbon coating is considered as the most promising option. Graphene is 
recognized as one of the most stable materials on earth, in addition, it only requires a single 
nanometer of carbon encasing the produced nanomagnets (Grass et al., 2007).  
 
 
Figure 2.25. Graphene-Coated Nanomagnete. Carbon Encasing Magnetic nanoparticles with 
two to four layers of graphitic carbon, TEM image of the nanoparticles (Mahmood et al., 2009) 
 
In addition to the protective function of coating to preserve the favorable properties of the 
magnetic core, graphene also offers a foundation for functionalizing the nanomagnets via 
attaching complex structures of a huge range of biomolecules. For instance, proteins, antibodies, 
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DNA and mRNA (Herrmann et al., 2009). The binding strength between the nanomagnet and the 
surface active molecules is so vital and it determines the overall performance. In actual fact, the 
carbon-carbon bond which constructs the backbone of almost all biological compounds is 
recognized as the strongest and most reliable chemical bond (Schätz et al., 2010).  
 
1.3 The Superiority of Graphitic Nanomagnets 
Conventional protection via thick polymer layers is available only in the micrometer-size, which 
is recognized as a sharp contrast to the final size obtained by coating with single nanometer layer 
of single or multiple graphene layer(s) (Herrmann et al., 2009).  
The limited magnetisation strength of the traditionally used metal oxides – e.g. iron 
oxides, is comparatively much lower than that of pure metals. Whilst, encapsulating pure 
magnetic metal inside the graphene coating grants an undiluted magnetisation and exceptionally 
improves the strength and reactivity (Grass et al., 2007). 
Graphene-coated nanomagnets have showed exceptionally high chemical stability under 
sever harsh conditions. Hermann and Stark at ETH Zurich investigated the thermal and chemical 
stability of the non-oxidic iron core-shell nanomagnets (i.e. iron carbide). About 80 wt % of the 
as-grown-carbon-coated iron carbide nanomagnets were successfully recovered after incubation 
for seven days in about 24 v% aqueous hydrochloric acid (i.e. pH<1). X-ray diffraction analysis 
confirmed that no phase transition occurred. Quite the opposite, naked magnetite readily 
dissolves within few seconds under similar strong acidic conditions (Herrmann et al., 2009).  
Dispersion is considered as one of the main challenging obstacles in biomedical 
applications, a variety of chemical adaptations have been theoretically and practically studied to 
exploit the solubility and dispersion of carbon nanostructures and overcome their tendency of 
aggregation. Well-designed surface engineering not only improves the dispersion efficiency but 
also develops their biocompatibility and enhances their capability to demonstrate high 
permeability and retention – EPR, which additionally improves their cellular uptake. The most 
important approaches for these modifications are generally categorized into two major groups (a) 
Covalent addition of chemical groups via reactions onto the π- conjugated skeletal structure of 
the graphene-coat and (b) Non-covalent adsorption of the supra-molecular groups, e.g. bio-
molecules, peptides and proteins (Tasis et al., 2006; Liang & Chen, 2010). 
81 
 
Recently, large numbers of in vitro and in vivo trials were performed in order to evaluate 
the potential cellular uptake of carbon-coated magnetic nanostructures and explore the 
relationships between their surface chemistry and biocompatibility. Professor Hwang and his 
group from Shandong University, in collaboration with St. Jude Children’s Research Hospital, 
USA, established a state-of-the-art experimental design in which they synthesized polymer 
grafted carbon-coated metallic iron nanoparticles with various surface chemistry modifications 
and investigated their oxidative stress, dynamic cellular response, cellular uptake and their 
effects on triggering cell apoptosis. Fruitfully, most of the surface modified carbon-coated iron 
nanoparticles presented high cellular uptake and insignificant cytotoxic effects which is 
considered as a great promise for widespread biomedical applications (Mua et al., 2010). 
 
1.4 Bioconjugation: Covalent and Non-Covalent Labeling 
1.4.1 Covalent Labeling 
Handling the as-produced carbon-coated nanostructures with a mixture of nitric acid and sulfuric 
acids was found effective to convert most of the terminal carbons, and the carbons at the defect 
site, into carboxylic groups (Wu et al., 2009). Subsequently, there are countless functional 
groups can be attached to these carboxylic ends and make possible of a wide range of bioactive 
compounds. The esterification of these carboxylic terminals may lead to high solubilization. 
However, these soluble oxidized structures still tend to aggregate in presence of salts because of 
charge-screening effects. Accordingly, they cannot be straightforwardly used for in vivo 
applications due to the expected high salt-content of most biological fluids, and also because 
further surface adjustments will be required. (Liu et al., 2009). 
Fluorination of the side-walls of the graphene-coated nanostructures takes place via a 
simple addition reaction. Such approach is considered very useful because further groups still 
can be attached through substitution of fluorine with various groups. For instance, alkyles, 
diamines and diols. Such amino alkylated surface can undergo further sophisticated 
functionalization utilizing these free amino groups in order to bind to many biological molecules 
for specific bio-medical applications (Wu et al., 2009).  
Cycloaddition is considered as one of the most widely used covalent addition reactions 
used to functionalize and efficiently disperse graphene-based nanostructures for biomedical 
applications. For instance, addition of azides takes place at the native aromatic side-walls of the 
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graphene outer-walls. Finally, addition of terminal amine-terminated poly ethylene glycols can 
be designed for biological applications (Liu et al., 2009). 
 
1.4.2 Non-Covalent Labeling 
Non-Covalent functionalization of carbon-coated nanostructures is usually accomplished by 
coating with surfactants and polymers of amphiphilic nature, given that the chemical structure of 
the π-network of the outermost graphene-layer is not affected. The characteristic poly-aromatic 
nature of the graphitic surface is easy to get-linked-to via numerous aromatic molecules by the 
aid of the π-π stacking. A notable study by Chen and Hongjie Dai at Stanford University showed 
that proteins can be firmly attached to the surface of hollow cylinders of rolled-graphene-sheet, 
i.e. single wall carbon nanotubes (SWNTs), functionalized by an amine-reactive pyrene 
derivative (Chen et al., 2001). Accordingly, aqueous solutions of the non-covalently bio-
engineered molecules’ show high potential for numerous biomedical applications particularly 
imaging, ultra high sensitive bio-sensoring and therapeutics (Wu et al., 2009; Liu et al., 2009).  
 
1.5 Diagnostic Applications: Thermoacoustic Imaging 
A variety of computerized tomographic techniques have had a massive impact on biomedical 
diagnostics. Furthermore, numerous methods are being developed (e.g., the “common” X-ray, 
single-photon emission, positron emission, ultrasound, magnetic resonance…etc) (Natterer, 
1986). The never-ending strive is to increase the resolution and contrast of the imaging 
techniques, and at the same time to reduce their cost and negative side-effects. Nonetheless, 
these objectives are usually contradictory. For example, some economical and significantly 
harmless techniques with high-resolution methods (e.g. ultrasound imaging) often do not provide 
good contrast in soft tissues, whereas, other techniques with good contrast (e.g. optical or 
electrical impedance tomography) suffer from low resolution. Recently, many researchers have 
been working on developing novel generations of hybrid techniques. Thermoacoustic 
tomography (TAT) is recognized as the most successful example of such hybridization 
approaches (Kruger et al., 2003).  
In TAT, a short-duration electromagnetic EM pulse is propelled through a biological 
object (e.g. abdominal cavity, skull or a woman’s breast). These EM waves will trigger the 
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generation of a thermoacoustic signal that can be detected via suitable transducers. Figure 2.26 
illustrates the production of the thermoacoustic signal. 
 
Figure 2.26. Thermoacoustic Signal Production. EM energy in is absorbed, producing heating, 
followed by sudden thermal expansion, which induces an outwardly propagating acoustic wave 
(Kruger et al., 2000) 
 
However, as a diagnostic tool neither radiofrequency RF waves nor visual light alone 
would provide acceptable resolution: (a) in case of RF, this is due to the long wavelength, yet, 
shorter microwaves still can be used, although this will drastically affect their penetrability, (b) 
in case of the optical region, the problem is with the multiple scattering of light. The absorption 
of the EM energy results in thermo-elastic expansion, and thus, a pressure wave which is a 
function of time and space/distance is generated. Such ultrasound signal can be measured by 
transducers placed around the object in a three dimensional setup. Indeed, the measuring scheme 
that utilizes two types of waves combines the high resolution of the ultrasound with the high 
contrast of EM waves. The advantages of using microwave induced thermoacoustic imaging 
MITI are utterly based on the simple relation (λ = c / ƒ). Where, frequency – ƒ which is inversely 
proportional to the wavelength – λ –  i.e. smaller wavelength results in better resolution, and the 
speed of light and sound in air are approximately 3 x 108 m/s and 330 m/s respectively. 
Therefore, MITI combines the privilege of both higher frequency and lower speed for better 
resolution, in addition, takes advantage of both pure ultrasound imaging and microwave imaging 
in order to obtain good spatial resolution and imaging contrast as well.  
In seeking higher resolution and contrast for early, and yet accurate, detection of various 
diseases many attempts are ongoing for in vivo contrast enhancement. A notable study by Nie et 
al. showed fivefold great thermoacoustic signal enhancement and much longer retention time. 
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When tumor bearing mice was intravenously injected with superparamagnetic magnetite 
nanoparticles coated with polyaniline and conjugated to folic acid which serves as a cancer-
biomarker-specific targeting ligand FA-Fe3O4/PANI (Nie et al., 2010). In conclusion, optimizing 
the design of the conjugate system – i.e. targeting ligand (e.g. sdAbs), magnetic material (e.g. 
Fe@C-MNP) and biocompatible coating (e.g. PEG and others) would have a tremendous impact 
on the quality of the diagnostic processes and subsequently on the efficacy of the therapeutic 
applications. 
 
1.6 Therapeutic Applications: Magneto Hyperthermia 
Magneto hyperthermia is a noninvasive technique that devastates diseases tissues, for instance, 
cancer cells, by transferring fatal dose of heat to the actively-targeted site of interest upon 
exposure to an oscillating external magnetic field while preserving surrounding vicinity of 
healthy tissues from any significant damage. 
 
1.6.1 Physicochemical Principles of Magneto Hyperthermia 
As previously explained, the hysteresis loop of macroscopic, bulk, ferromagnetic materials (see 
Figure 2.22) is primarily responsible for the heat generation when an external oscillating 
electromagnetic field is applied to a colloidal system of magnetic material. Upon exposure to a 
properly intense alternating field, the material will continuously get magnetized and 
demagnetized according to its hysteresis loop curve while each cycle leads to the release of 
energy in the form of heat.  
In sharp disparity, upon application of an external oscillating magnetic field to 
superparamagnetic nanoparticles, which are intrinsically in constant rotation due to their very 
small thermal energy barrier, the heat generated results from two different relaxation 
mechanisms (i) Néel and (ii) Brownian relaxations. In case of Néel’s, the produced heat is due to 
the occurrence of rapid alteration in the orientation of the magnetic moments correlated to its 
crystal lattice’s arrangement – i.e. it is an internal dynamic process. The continuous change of 
the directions is hindered by the anisotropic energy barrier of the crystal lattice which will 
typically tend to direct the magnetic domains in the most energetically favorable orientation. 
Heat loss in the form of thermal relaxation arises as a result of overcoming these energy barriers 
(Kumar & Mohammad, 2011). In case of Brownian relaxation, the produced heat is due to the 
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physical rotation of the particles themselves in the surrounding medium – i.e. it is an external 
dynamic process, in which the rheological properties of the medium (i.e. viscosity and fluid 
dynamics) where the magnetic nanoparticles MNPs are placed will, to a great extent, affect the 
amount of the heat generated since the heat dissipation is mainly created by the frictional forces 
created during the physical rotation (Kumar & Mohammad, 2011). Figure 2.27 illustrates the 
two different mechanism of relaxation. In case of the internal dynamic Néel relaxation mode the 
crystal lattice configuration of the nanoparticles rotate so as to align themselves according to the 
external field directions while overcoming the crystal lattice energy barrier. In case of the 
external dynamic Brownian relaxation mode, the entire particle will continuously tend to align 
itself in accordance to the external field which typically produce a localized friction forces with 
the surrounding media and subsequently produces heat (Mornet et al., 2004). 
 
Figure 2.27. Néel and Brownian Relaxation Mechanisms (Mornet et al., 2004) 
 
The specific absorption rate SAR of MNPs represents the slope of the time-dependent 
temperature curve. The SAR is a useful parameter to contrast the heating capability of different 
magnetic nanoparticles. In addition, it is used for evaluating their selection.  
𝑆𝑆𝑆𝑆𝑆𝑆 = c𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑
 
Where: c corresponds to the heat capacity of the solution, T for temperature and t for time. 
A new term which was only proposed in 2009, and is not yet well-known defined as 
intrinsic loss power ILP, the advantage of the new term that it lacks the extrinsic parameters – 
86 
 
i.e. frequency and field amplitude. Therefore, the inherent heating ability of the nanoparticles can 
be expressively compared. The ILP is more suitable for superparamagnetic nanoparticles and is 
also valid for frequencies up to 900 kHz, this range is commonly applied for most biomedical 
applications (Kallumadil et al., 2009; Kumar & Mohammad, 2011).  
Multifunctional graphitic magnetic nanomaterials (e.g. cobalt and iron) have been 
synthesized by different methods. For instance, flame spray (Grass et al., 2007; Herrmann et al., 
2009), microwave arch discharge (Hsin et al., 2008; Liang et al., 2008), chemical vapor 
condensation/deposition (Wang et al., 2003) and ultrahigh sonic power (Nikitenko et al., 2001). 
All synthesized particles were directly administered to their targets (e.g. cancerous HeLa cell 
cultures) and lacked the targeting moieties which in general hindered the impracticability of such 
nanostructures and severely reduced their ability of reaching certain diseased spots where direct 
injection would not be possible. After a proper incubation time, usually 24 hours, it was found 
that according to their size ranges, the carbon-coated nanomagnets were up-taken inside various 
sub-compartments of the target cells. Electromagnetic radiation of radiofrequency ranges 100-
1000 kHz typically applied to cell cultures due to their high penetrability (Young et al., 1980) 
and high bio-tolerance (Nikiforov, 2007). In most of the cases, it was found that the graphitic 
materials are strong absorbers of the exposed radiation, such absorbance was reflected in an 
elevated localized heating inside the diseased cells. In addition, the nanoparticles were found to 
induce localized damage of the cellular DNA and various membranes integrity, which was 
reflected in the stimulation of cellular apoptosis (Mahmood et al., 2009; Xu et al., 2010). Even 
so, various MNPs are FDA approved while others are still in the process of getting approved. 
 
Table 2.14. Commercially Available MNPs Currently FDA Approved (Cole et al., 2011) 
Pre-Clinical Agent Commercial Name Target Status 
AMI-25 Ferumoxide, Feridex, Endoderm Liver Approved 
OMP Abdoscan Bowel Approved 
AMI-227 Combidex, Sinerem, Ferumoxtran Lymph Node Phase III 
CODE 7228 Feraheme, Ferumoxytol Vasculature Phase II 
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1.7 Nano-Magnetism from Ferro to Superparamagnets: The Epilogue 
Momentous development has been made with respect to magnetic nanostructures platforms for a 
huge range of magneto hyperthermia applications, particularly for cancer treatment. However, 
there are still gaps in the awareness and technical capacity which avert such progresses from 
being transferred from the lab-bench-tops to the bed-sides in clinic. In addition, limitations exist 
for targeting effectiveness, predominantly with respect to active/magnetic targeting. 
Furthermore, there has been recently more focus on understanding the biocompatibility and 
cellular cytotoxic concerns for the implementation of nanotechnology in biomedical theranostics 
fields. The majority of the currently ongoing studies still limited to be conducted only for in vitro 
diagnostic applications, whereas, meticulous testing still need to be conducted for in vivo 
diagnostic and therapeutic applications as well.  
 
2 Construction and Radioactive Labeling of sdAbs-Fe@C-MNPs Conjugate 
Thanks to the particular properties of single domain antibodies, they have high potential for 
immuno imaging. A technique has recently been developed at the In vivo Cellular and Molecular 
Imaging (ICMI) Laboratory of the Nuclear Medicine Department, UZ Brussels, to generate 
highly specific radiotracers based on sdAbs (Vaneycken et al., 2011). The technique takes 
advantage of the His-tag that these recombinant molecules contain to form a coordination bond 
with Tri-carbonyl Metastable Technetium [99mTc(CO)3(H2O)3]+ which is used for obtaining high 
definition images with the aid of single-photon emission computed tomography SPECT (Xavier 
et al., 2012). 
Another interesting technique in imaging is active/magnetic directing of magnetized 
tracers to a specific site of interest within the body – i.e. organ or sub-organ’s location of interest, 
using an external focalized magnetic field. In view of a better trespassing, and penetrability, of 
these markers through physical boarders, the main aim was to bring this technique to the nano-
scale. Therefore, a method to conjugate sdAbs to nanosized magnetic graphene-coated particles 
has been developed at Faculty of Science and Bio-engineering, Vrije Universiteit Brussel (VUB) 
in collaboration with School of Science and Engineering (SSE), The American University in 
Cairo (AUC).  For this purpose, carbon-coated metallic Iron nano magnetic beads of an average 
diameter 50 nm and exhibiting terminal carboxyl functional groups are conjugated to sdAbs. The 
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hereby applied coupling is based on the formation of peptide bonds using water-soluble 1-Ethyl-
3-(3-Dimethylaminopropyl)Carbodiimide (ECD) and N-Hydroxysuccinimide (NHS).  
 
2.1 Applied Chemistry 
2.1.1 General Principle 
The Fe@C-MNPs conjugation reaction is based on the formation of peptide bonds by 
condensation reaction of terminal carboxyl groups formed on the surface of the MNPs with the 
amino groups, particularly from lysine, of the sdAb. On the other hand, the chelating of 
[99mTc(CO)3(H2O)3]+  is specifically directed  to the (His)6 tag of the sdAbs to form a strong 
coordination bond. In both reactions, amine groups are involved, where the differentiation 
between histidine and non-histidine coupling is achieved by conducting two consecutive 
reactions at different pH values.  Indeed, the residue of histidine is an imidazole containing 
molecule in which the double bound nitrogen atom in the aromatic ring is protonated at pH ≤ 6.  
As a consequence, there would be no nucleophilic attack on the carbon of a carboxyl group at pH 
lower than 6. Figure 2.28 illustrates all the protonation states of the histidine residues at different 
pH values. 
 
Figure 2.28. Protonation States of Histidine at Different pH Values (Li & Hong, 2011) 
 
In sharp contrast, the amino groups of lysine residues are still unprotonated at pH ≤ 6, 
and peptide bonds between terminal functional carboxyl groups of the Fe@C-MNP and the 
lysine amino groups of a protein can be formed. The coupling system generated between the 
water-soluble carbodiimide (EDC) / N-hydroxysuccinimide (NHS) has its optimum at (pH 5.5). 
The hereby presented procedure consists of (a) first performing the condensation reaction at (pH 
5.5) with the EDC/NHS system, directed to non-histidine residues (i.e. Lys) amines, then (b) 
followed by the His-directed radioactive labeling of the sdAb-Fe@C-MNPs complex 
with[99mTc(CO)3(H2O)3]+  at relatively higher pH value (i.e. pH 7.4) and temperature 50°C. 
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Noteworthy, both of the sdAbs as well as carboxylated magnetic beads remain highly stable 
under in these harsh conditions. 
 
2.1.2 Preparation of His6-Tag Anti-GFP and Ni-NTA Magnetic-Beads Conjugate 
The binding affinity of the conjugated sdAb was examined through performing a simple, and 
straightforward, conjugation between the (His)6-taged sdAb (e.g. anti-GFP sdAb) and the nickel-
nitrilotriacetic acid Ni-NTA functionalized magnetic beads from QuickPick™ IMAC. The 
remaining GFP content is typically estimated through measuring the fluorescence peak which 
exists at a wave length of about 488 nm. The conjugation conditions of the preliminary test are 
now used as a basis for this protocol, but should be further optimized. 
 
2.1.3 The Non-His Conjugation of sdAb to Fe@C-MNPs 
The non-His conjugation between the antibodies and the graphene-coated magnetic nanoparticles 
is performed with a classical condensation reaction using carbodiimide as intermediate, whereby 
the carboxyl groups of the magnetic beads react with the primary amine groups (i.e. terminal or 
intermediate groups) of the sdAb in order to form a peptide bond. 
 
 
Figure 2.29.General Reaction of the Formation of a Peptide Bond. Starting from a carboxyl 
group and a primary amine group, using a carbodiimide, which is taking part in the reaction but 
does not appear in the final product (Li & Hong, 2011) 
 
Figure 2.30 illustrates the reaction mechanism involves the presence of carboxylic group 
from the first molecule and the EDC crosslinker in order to form the first unstable intermediate 
(o-Acylisourea) which in the presence of N-hydroxysuccinimide (NHS) is transformed into the 
corresponding urea and a more stable carboxy-succinimide ester. The latter reacts spontaneously 
with primary amines from another molecule 2 to form the peptide bond. 
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 Figure 2.30. Carboxyl-to-Amine Crosslinking Using the Carbodiimide EDC and Sulfo-NHS. 
The formed carboxy-succinimide ester reacts spontaneously with primary amines, leading to the 
aimed peptide bonds (Pierce, 2012) 
 
The hereby described procedure activates the carboxyl groups of the magnetic beads with 
the water soluble EDC and NHS. This system has an optimum performance at (pH 5.5), a 
condition where histidine molecules do not react. 
  
2.1.4 The His-Tag Specific Labeling of sdAb with 99mTc 
His-tagged sdAbs are particularly suited for 99mTc-labeling via tricarbonyl chemistry. Indeed, 
histidines have proven to coordinate efficiently to the tricarbonyl core of 99mTc-tricarbonyl 
(Garayoa, 2002; Xavier et al., 2012)  
 
Figure 2.31. Technetium Labelling of a Biomolecule Through the Tc-tricarbonyl Synthon 
(Garayoa, 2002) 
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Crystallography studies have also proofed that the His-tag on sdAbs is located on the 
opposite side of the paratope (Vincke et al., 2009). Hence, it minimizes the risk of interference 
with antigen-binding capability. Finally, the high thermal and chemical stabilities have been 
recognized as essential criteria for efficient complexation of the 99mTc-tricarbonyl to His-tagged 
antibody fragments (Broisat et al., 2012), and these high stability properties are a typical feature 
of SdAb (Dumoulin et al., 2002).  
The complete labeling procedure has been described by Catarina Xavier et al., and starts 
with the generation and purity assessment of the 99mTc-tricarbonyl precursor. Afterward, it is 
followed by a set of straightforward procedures for the sake of complexing the precursor with the 
His-tagged sdAbs. Finally, various ways are applied to evaluate the radiochemical purity of the 
obtained sdAb-Fe@C-MNP derived radiotracer conjugate (Xavier et al., 2012). 
 
3 Materials and Methods 
3.1 Materials 
3.1.1 Reagents and Buffers 
 
Table 2.15. Reagents and Buffers used in this research 
Reagents and Buffers Composition Supplier 
Carboxylated Magnetic Beads 25-50 nm Fe@C-MNP 
concentration 30 mg/mL 
suspended in 5 mL H2O 
5 x 1013 Particles/mL 
8.7 x 1017 mmol (-COOH)3/ Particle  
TurboBeads® 
QuickPick™ IMAC metal affinity kit for proteins Bionobile 
IMAC Magnetic Particles IMAC magnetic particles in PBS 
buffer adjust pH 7.0, 1M NaCl, 
0.05 % Tween-20, 0.02 % NaN3 
Bionobile 
IMAC Regeneration Buffer Aqueous NiSO4 solution,  
0.05 % Tween-20, 0.02 % NaN3 
Bionobile 
  
                                                 
3 The beads are functionalized with 2-Phenylethylamine and 3-Phenylpropanoic acid groups respectively 
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Reagents and Buffers Composition Supplier 
IMAC Imidazole Buffer, 500 
mM 
500 mM imidazole in PBS buffer  
adjust (pH 7.0), 0.02 % NaN3 
Bionobile 
IMAC2x Wash Stock Buffer PBS buffer (pH 7.0), 1 M NaCl,  
0.05 % Tween-20, 0.04 % NaN3 
Bionobile 
IMAC Wash Buffer 1 1700 µL IMAC2x wash buffer 
1700 µL H2O 
Bionobile 
IMAC Wash Buffer 2 1700 µL IMAC2x wash buffer 
135 µL Imidazole buffer 500 mM 
Bionobile 
IMAC Wash Buffer 3 1700 µL IMAC2x wash buffer 
270 µL Imidazole buffer 500 mM 
680 µL 5 M NaCl 
750 µL H2O 
Bionobile 
IMAC Elution Buffer 20 mM Tris-HCl (pH 8.0), 250 mM 
NaCl, 300 mM imidazole, 
0.05 % Tween-20, 0.02 % NaN3 
Bionobile 
MES Buffer 
(2-(4-Morpholino) 
ethanesulfonic acid 
1.06 g MES 
dissolve in 90 mL H2O 
adjust pH to 5.5 
adjust final volume to 100 mL 
Sigma-Aldrich 
PBS/Tween Buffer PBS buffer 
adjust pH to 7.4 
0.05 % Tween-20 
Sigma-Aldrich 
EDC Solution 10 mg/mL EDC in MES buffer Sigma-Aldrich 
NHS Solution 10 mg/mL NHS in MES buffer Sigma-Aldrich 
Lyophilized kit IsoLinkTM 4.5 mg of sodium boranocarbonate 
2.85 mg of sodium tetraborate.10H2O 
8.5 mg of sodium tartrate.2H2O 
7.15 mg of sodium carbonate, pH 10.5 
Covidien 
Hydrochloric Acid 1 M HCl in H2O Sigma-Aldrich 
His-tagged anti-VCAM sdAb 1 mg/mL sdAb in PBS buffer CMIM, VUB 
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Reagents and Buffers Composition Supplier 
His-tagged anti-HER2 sdAb 1 mg/mL sdAb in PBS buffer CMIM, VUB 
His-tagged anti-GFP sdAb 1 mg/mL sdAb in PBS buffer CMIM, VUB 
eGFP protein 1 mg/mL eGFP in PBS buffer CMIM, VUB 
Instant Thin Layer 
Chromatography ITLC Eluent 
acetone Sigma-Aldrich 
 
3.1.2 Equipments and Consumables 
Table 2.16. Equipments and Consumables used in this research 
Equipment/Consumable  Supplier 
99Mo/99mTc Generator Drytec, GE Healthcare 
Ventilated hood with leaded-shield GE Healthcare 
PickPen® Magnet  Bionobile 
PickPen® tips  Bionobile 
Vivaspin® HY 5000  VIVAPRODUCTS 
Water bath  Eppendorf 
Polycarbonate microtubes Sigma-Aldrich 
Silica gel impregnated glass fiber sheets Pall Corporation, Life Sciences 
Gamma counter Drytec, GE Healthcare 
Ultrasonic homogenizer Hielscher 
 
3.2 Methods 
3.2.1  Preparation of His6-Tag Anti-GFP sdAb and Ni-NTA Magnetic-Beads Conjugate 
The main motive behind performing this experiment was to confirm (a) the preservation of the 
binding affinity of the conjugated sdAb and (b) the absence of any shielding or masking effect on 
its active paratopes. In order to optimize the ratio between anti-GFP and Ni-NTA magnetic beads 
(i.e. QuickPick™ IMAC) during conjugation, different concentrations of anti-GFP for a constant 
amount of magnetic beads were tested.  
Procedure 
1. In order to avoid any unspecific binding of the His-tagged eGFP protein, the protein 
sample was washed with IMAC wash buffer 1. 
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2. Tubes were numbered and filled up with sample/solutions as follows: 
 Tube 1: 100 µL IMAC Magnetic Particles 
 Tube 2: 400 µL IMAC Regeneration Buffer 
 Tube 3: 400 µL IMAC Wash Buffer 1 
 Tube 4: 300 µL eGFP Protein Sample 
 Tube 5: 400 µL IMAC Wash Buffer 2 
 Tube 6: 400 µL IMAC Wash Buffer 3 
 Tube 7:   50 µL IMAC Elution Buffer 
Caution: Mix the IMAC magnetic particles suspension thoroughly before pipetting into 
microtubes, in addition, higher yields can be obtained by optimizing the incubation time. 
3. The PickPen® was dressed up with its tip and immersed in tube 1 to collect all the 
magnetic beads, then, released into tube 2 with gentle mixing. 
4. The magnetic beads was collected from tube 2 and released into tube 3 and gently 
mixed using the PickPen® tip. 
5. The magnetic beads were collected from tube 3 and transferred to tube 4 where they 
were incubated for 15 min. The solution was mixed occasionally to avoid 
sedimentation. 
6. After incubation, the beads were collected and washed in tube 5 by gentle mixing for 
at least 10 sec, followed by further washing in tube 6 for at least 10 sec. 
7. Finally, the washed beads were collected and transferred to tube 7 (containing the 
elution buffer), mixed thoroughly and incubated for at least 2 min. The solution was 
mixed occasionally to avoid sedimentation. 
8. After incubation, the magnetic beads were collected and discarded and the purified 
His-tagged protein was transferred into new microtube. 
9. The fluorescent peak of the remaining solution from tube 7 was measured at OD448nm 
using Nanodrop® spectrophotometer. 
 
3.2.2  Preparation of sdAb and Carboxylated Fe@C-MNPs Conjugate via EDC/NHS 
Based on the above optimization test, a ratio of approximately 10/1 weight/weight is considered 
between the Fe@C-MNPs magnetic beads and the sdAb. That is to say, 50 µL magnetic beads 
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suspension (about 1.5 mg magnetic beads) should couple to 50 µg of sdAb (i.e. 50 µL anti-eGFP, 
anti-VCAM and anti-HER2 sdAbs). 
Procedure 
1. The carboxylated Fe@C-MNPs magnetic beads was homogenously dispersed using a 
sonicator with 10 x 5 sec pulses, with interval times of about 10 sec. 
2. After sonication, the beads were brought up to room temperature, then 50 µL of the 
beads suspension was transferred into a new 2 mL polycarbonate microtube 
containing 200 µL MES buffer for washing via gentle mixing using the PickPen® tip. 
3. The beads were collected and washed again after being transferred into another 
microtube containing 200 µL of MES buffer. Finally, the beaded were collected and 
transferred into a microtube containing 50 µL of MES buffer. 
4. An equal volume of EDC solution was added – i.e. 50 µL EDC. Then immediately 
followed by addition of another 50 µL NHS solution. Finally, the mixture was 
incubated at room temperature for 20 min with continuous gentle agitation. 
5. The as-produced sdAbs (i.e. sdAb in PBS buffer) were prone to change their buffer 
into MES buffer via several centrifugation cycles using Vivaspin® HY 5000 tubes, 
then concentrated up to a final concentration of about 1.0 mg/mL. 
6. After incubation, the activated magnetic beads were collected and transferred into the 
microtubes containing 50 µL of each sdAb. The mixture was incubated with 
continuous shaking for about 30 min. 
7. After incubation, the conjugated beads were collected and washed 3 times in 3 
consecutive microtubes containing 200 µL PBS/Tween. Finally, beads were collected 
and redispersed via vortex in 100 µL PBS/Tween. 
8. In order to confirm the preservation of the binding affinity of the sdAb conjugated to 
the carboxylated magnetic beads via EDC/NHS method. All the conjugated anti-GFP-
Fe@C-MNPs were collected and transferred into new microtube containing eGFP 
protein sample of the same concentration (i.e. Tube 4) as described earlier. 
9. The fluorescent peak of the remaining solution from tube 7 was measured at OD448nm 
using Nanodrop® spectrophotometer. 
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3.2.3 Radioactive Labeling of sdAb-Fe@C-MNP Conjugate 
Utilizing the well established technique of radioactive labeling of the single domain antibodies 
(Xavier et al., 2012) paved the road for the subsequent labeling of the entire conjugate – i.e. 
single domain antibodies and the graphene-coated magnetic nanoparticles. Such radio-labeled 
bio-nanostructure would present a very informative tool for a wide range of applications, for 
instance: (a) confirming and optimizing the EDC/NHS bioconjugation and (b) enabling the 
characterization and imaging of the actively targeted magnetic nanoparticles which will 
possibility impact both in vitro and in vivo theranostic applications under the gamma camera and 
MRI machines respectively. The purpose of this section is to show in step-by-step manner the 
easy way of preparing the radioactive precursors followed by the radioactive labeling with 99mTc-
Tricarbonyl, and then afterwards, instant thin layer chromatography analysis for assessment of 
radiochemical purity of labeled conjugate and finally the characterization of the capability of 
magnetic targeting under gamma camera will be addressed as well.      
  
A. Preparation of 99mTc-Tricarbonyl Precursor 
Procedure 
1. Exactly 1 mL of the 99mTcO4- solution which was previously prepared by the 
99Mo/99mTc generator, with radioactivity of about 0.74 – 3.7 GBq was added to the 
IsoLink™ kit. 
2. The mixture was incubated at 100 °C for about 20 min. 
3. After incubation, the reaction mixture was cooled down in water bath and brought to 
room temperature. 
4. Finally, the pH of the reaction mixture was adjusted to 7.4 using 1 M HCl. 
 
B. Radioactive labeling of sdAb-Fe@C-MNP Conjugate with 99mTc-Tricarbonyl 
Procedure 
1. Approximately, 50 µL of the sdAbs and free Fe@C-MNPs were added to about 450 
µL of fac-[99mTc(CO)3(H2O)3]+ at a pH 7.4. 
2. About 250 µL of the sdAb-Fe@C-MNP conjugate in PBS was added to about 250 µL 
of fac-[99mTc(CO)3(H2O)3]+ at a pH 7.4. 
3. The reaction mixtures were incubated at 50 °C for about 60 - 90 min. 
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Caution: The temperature of incubation depends on the thermostability of the sdAb, it is 
always recommended to determine, in advance, the melting temperature (Tm) of sdAb to 
be labeled. 
4. The labeled conjugate was separated from the free 99mTc-Tricarbonyl and 99mTcO4- 
via PickPen® or conventional magnet bar. 
 
C. ITLC analysis for Assessment of Radiochemical Purity 
Procedure 
1. About 2 µL of the 99mTc-Tricarbonyl labeled conjugate solution was added onto a 
15mm x 200 mm silica gel impregnated glass fiber sheet. 
2. The ITLC chromatogram was developed in acetone. 
3. The distribution of radioactivity was analyzed by scanning with a γ-radiation TLC 
scanner or counting the strip cut in 3 parts (i.e. application point, middle, solvent 
front) in a dose calibrator or gamma counter. Knowing that, the 99mTc-Tricarbonyl 
precursor and the 99mTcO4- reveal a retention factor value (Rf) of 1, whereas, the 
99mTc-Tricarbonyl-Conjugate has an Rf of about Zero.  
 
3.2.4 Magnetic Targeting of the Radio Labeled sdAb-Fe@C-MNP Conjugate 
The application of an external magnetic field by using a commercial standard magnet bar (i.e. ≤
0.55 Tesla) was performed under a gamma camera for two main reasons:  
 Confirming the attachment of the radiolabeled sdAb to the graphene-coated magnetic 
nanoparticles.  
 Proofing the concept of magnetic targeting function for the entire conjugate when it is 
placed in a phosphate buffered saline at the natural physiological criteria. 
Procedure 
1. The radiolabeled conjugate was transferred to a PBS/Tween (pH 7.4) filled 100mm 
dia. x 15mm H round Petri dishes and 50 mL Falcon tubes. 
Caution: All the radiolabeled solutions must be handled with great care to avoid 
radioactive contamination. 
2. Place the Petri dishes and the Falcon tubes under a gamma camera for capturing 
images at static conditions for at least 4 min.   
98 
 
3. An external positioned magnet (i.e. < 0.55 Tesla) was placed while running the 
gamma camera and continued capturing images. 
4. The magnet was removed and the gamma camera continued capturing image after 
removal for at least 1 min.  
 
4 Results and Discussion   
4.1 His6-Tag Anti-GFP sdAb and Ni-NTA Magnetic-Beads Conjugate 
After conjugating the His6-tagged anti-GFP to the Ni-NTA magnetic beads from QuickPick™ 
IMAC the concentration of the eGFP protein content was measured using Nanodrop 
spectrophotometer at OD280nm and OD488nm.  
Table 2.17 illustrates the initial and final concentrations and absorbance values of the eGFP 
proteins after purification using NI-NTA magnetic beads. 
 
Table 2.17. Concentration of eGFP Proteins before and after Magnetic Purification 
Protein 
Initial Conc. 
(mg/mL) 
Initial Absorb. 
(a.u.) 4 
Final Conc. 
(mg/mL) 
Final Absorb. 
(a.u.) 
eGFP – 25 µL 0.21 0.449 0.00 -0.206 
eGFP – 50 µL 0.47 0.945 0.14 0.291 
eGFP – 100 µL 0.95 1.798 0.29 0.621 
 
In addition, the fluorescent finger print of the eGFP protein was reduced in equivalence to the 
above results. Finally, the optimum obtained results came from using a 50 µg of sdAb per 1.5 mg 
(i.e. 50 µL) of magnetic beads. 
 
4.2 Preparation of Anti-GFP sdAb and Fe@C-MNPs Conjugate via EDC/NHS 
The optimized set-up from the previous experiment was used to evaluate the conjugation’s 
efficiency of the anti-GFP sdAb conjugated to 25-50 nm Fe@C-MNPs via EDC/NHS method. 
Table 2.18 represents the initial and final concentration of the eGFP protein after magnetic 
purification using the PickPen® magnet. 
                                                 
4 Absorbance Units 
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Table 2.18. Concentration of eGFP Proteins before & after Fe@C-MNPs Magnetic Purification 
Protein 
Initial Conc. 
(mg/mL) 
Initial Absorb. 
(a.u.) 
Final Conc. 
(mg/mL) 
Final Absorb. 
(a.u.) 
eGFP – 50 µL 0.44 0.913 0.12 0.314 
 
In the same way, the fluorescent finger print of the eGFP protein at OD448nm was reduced in 
equivalence to the obtained results. Certainly, both of the Ni-NTA magnetic beads as well as the 
Fe@C-MNP were able to get conjugated to the anti-GFP sdAb with equal efficiency. In addition, 
with the aid of an external magnet they could, powerfully, collect their specific target antigen 
(i.e. the eGFP protein) from the PBS buffer. In conclusion, the EDC/NHS conjugation did not 
affect the antigen binding capacity of the sdAbs and preserved their immunogenicity. 
 
4.3 Radioactive Labeling of sdAb-Fe@C-MNP Conjugate 
After the radioactive precursor was prepared it was incubated with the reagents as follows: 
 50 µL Free Fe@C-MNP + 450 µL [99mTc(CO)3]7+ 
 50 µL Anti-HER2 sdAb + 450 µL [99mTc(CO)3]7+ 
 50 µL Anti-VCAM sdAb + 450 µL [99mTc(CO)3]7+ 
 250 µL Anti-VCAM sdAb-Fe@C-MNP Conjugate +  250 µL [99mTc(CO)3]7+ 
 250 µL Anti-HER2 sdAb-Fe@C-MNP Conjugate +  250 µL [99mTc(CO)3]7+ 
 
Table 2.19 illustrates the initial and final activities of the free graphene-coated magnetic 
nanoparticles, as well as, those of the different prepared conjugates in accordance to their 
incubation times.   
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Table 2.19. Radioactivity of the Radiolabeled Reagents and Conjugates 
Reagent/Conjugate 
Initial Activity 
(µCi)5 
Final Activity 
(µCi) 
Incubation 
Time 
Labeling 
(%) 
Free Fe@C-MNP 2.99 0.34 2 hr 03 min 11.4 
α-VCAM Conjugate 2.83 0.685 2 hr 29 min 20 
α-HER2 Conjugate 2.75 0.89 2 hr 56 min 25 
Free α-HER2 sdAb 4.68 3.84 1 hr 46 min > 99 
Free α-VCAM sdAb 5.05 4.1 1 hr 47 min ≈ 93 
 
The naked graphene-coated magnetic beads showed 11.4% labeling capacity which might be 
considered as non-specific binding to the particles, however, the radioactivity of the magnetic 
particles will be added to the whole conjugate and will serve for the benefit of the 
tracing/imaging experiments.  
 
4.4 Magnetic Targeting of the Radio Labeled sdAb-Fe@C-MNP Conjugate 
After transferring the radiolabeled content of the conjugated sdAb to Petri dishes and Falcon 
tubes filled with PBS/Tween, they were placed under dynamic gamma camera (i.e. 1 frame/s) for 
characterization and visualizing the effect of placing an externally position, commercially 
standard, magnet bar of an intensity < 0.55 Tesla. Figure 2.32A represents the qualitative 
analysis of the initial static condition of the fully dispersed radiolabeled sdAb conjugates (i.e. α-
VCAM- and α-HER2-Fe@C-MNP conjugates), while Figure 2.32B represents the focalization 
effect of placing an external magnet bar. The increase in intensity is mainly concluded by the 
attraction of the dispersed magnetic particles to the externally positioned magnet, which confirm 
the binding between the radiolabeled single domain antibody and the graphene-coated metallic 
Iron magnetic nanoparticles.   
 
                                                 
5 1 microcurie (µCi) = 37 kilobecquerel (kBq) 
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Figure 2.32. Qualitative Analysis of Magnet Focalization of the Radiolabeled Conjugate. A. 
Represents the initial static condition, while, B. Represents the focalization effected obtained 
after application of the external magnet. 
 
Figure 2.33 illustrates the quantitative analysis of the focalization effect in the Petri dish, 
in the beginning, the magnet was placed after one minute of capturing time, a fast focalization 
took place (i.e. from ≈ 2.5% to 20%), then followed by slow increase over extra four minutes in 
the radioactivity till it reached about 32% of the total radioactivity sensed in the entire containing 
medium.  
 
Figure 2.33. Quantitative Analysis of Magnet Focalization of the Radiolabeled Conjugate 
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5 Conclusion 
 
The properties of the single domain antibodies were combined with the vast growing 
nanotechnology. In general, any diagnostic and/or therapeutic application will require certain 
predefine multifunctional criteria, above and beyond is the presence of a smart targeting moiety 
which is able to deliver the attached loads to its corresponding site with minimal/insignificant 
non specific targeting. In the current study, sdAbs were selected to represent the specific 
targeting agent and the nanomagnetism was selected to express the superiority of 
nanotechnology in constructing such a system of high biocompatibility and easy-tailored 
physiochemical properties which can be predesigned to serve for diagnostic as well as 
therapeutic applications.    
The distinctive inherent ferro and superparamagnetic properties combined with the 
superior chemical, thermal and biological stabilities of the multilayered graphene-coating have a 
wide range of novel and efficient tools for highly multipurpose applications – i.e. diagnostic and 
therapeutic fields. Worth mentioning, their brilliant properties enable them to effectively impact 
other different fields as well – i.e. environmental, agricultural, chemical and industrial. The 
implementation of the currently available simple and mass-scalable synthetic methods would 
provide high control over size and shape which will supply economic and eco-friendly 
candidates for future research works. Finally, the development of novel functionalization 
protocols together with new-fangled smart targeting ligands – e.g. sdAbs, will sincerely lead to 
the generation of a new epoch of scientific researches which will pave the road for a new era of 
noninvasive and side-effects’ free theranostic means.  
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CONCLUDING REMARKS AND FUTURE CHALLENGES 
 
Schistosomiasis: the disease, the severity of the gap in the present intensity of applied research 
workloads and the scarce sensibility of withdrawn attention incited the authors of this research 
work to conduct the current research. Neglected tropical diseases as “Bilharziasis” infects at least 
200 million individuals in 75 countries,  while 120 million people are symptomatic patients, a 
further 600 million people are still exposed to infection and are potentially victim of this parasite 
(WHO, 2010), which causes brutal debilitating and incapacitating illness in millions of human 
and cattle. The annual death of Schistosomiasis was recently estimated by 150 – 200 thousand 
people every year, adding to that the drastic impact on economical and nutritional aspects 
(Blyther, 2011).  
 The development of a novel theranostic agent was the main target, in order to get it 
accomplished the single-domain antibody technology was selected to design a stable and 
efficient targeting moiety. In addition, the implementation of the vast growing nanotechnology 
was established via two major joint aspects (a) Nanobodies® technology, which, by itself, can 
afford a serological and therapeutic tool and (b) Graphene-coated magnetic nano-system, which 
can provide a complementary diagnostic and therapeutic function. The distinctive combined 
properties (i.e. high affinity, thermal and chemical stability, efficient synthesis, plus the 
synergistic active and magnetic in vivo/in vitro targeting ability) of the pre-designed system are, 
so far, confined in a nanoscale dimensions which sequentially added a wide-range of theranostic 
possibilities and applications.     
 The research described in this thesis resulted in the following methodological novelties: 
 Nanobodies® against two different Schistosoma mansoni antigens, gut specific 
antigen and excretory-secretory antigen, 
 Active sdAb-Graphene-Coated-Nanomagnet Bioconjugate, 
 99mTc Labeled active conjugate. 
The research described in this thesis led to the following important biological 
conclusions: 
 SmCB antigen was recognized as a potent immunogenic antigen and could 
elicit proper immune response in Camelidae’s which subsequently lead to the 
production and purification of antigen-specific sdAbs binders, 
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 The bioconjugation of sdAb-Fe@C-MNP via EDC/NHS method showed a 
high preservation of the binding affinity of the attached Nanobodies®, 
 The radiolabeled active bio-nano-system could successfully be externally 
directed through a simple magnetic targeting process. 
The number of reports dealing with bio-nanotechnology applications in different fields 
clearly indicates that this class of bio-nanostructure system represents an important tool for 
research as well as biotechnological uses, particularly theranostic ones. Despite the advantages of 
single domain antibody in terms of unique structural features, stability, and production costs the 
technology has taken almost twenty years and yet not largely popular in the scientific area. Part 
of the problem comes from the pretty restrictive intellectual property policy introduced by 
Hamers’ patents which has probably prevented other contributors from participating in the 
development. In addition, there are quite a lot of technical challenges that still need to be studied 
in a systematic way, at the recombinant antibody panning level, plus, the level of the pre and post 
production strategies. For instance: 
 Although Nanobodies® usually exhibit high expression yield, inadvertently, those 
of high binding affinity may suffer from very low expression.  
 Some of the developed sdAbs may show excellent performance, yet, lack stability 
upon prolonged storage (e.g. dimerization), which necessitates an afterward 
genetic engineering intervention. 
 The clearance time is a very crucial factor that it may act as a double-edged 
sword, several techniques need to be developed to control the optimal blood 
circulating time. 
 The undesired accumulation in kidney still requires further investigation for 
finding the reason and discovering appropriate solutions. 
 Tailoring into pluripotent constructs of Nanobodies® and their fusion derivates as 
well as their heterogeneous conjugate systems.  
 
Finally, the single-domain antibody original patents are expiring in the next year along 
with the recent accessibility of new libraries, protocols, and vectors suitable for different 
theranostic applications. Therefore, it is strongly expected to have an increase of the interest of 
both research and industry for this class of sdAb bio-nano-technology in the near future. 
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